



(51) International Patent Classification:

C07D 491/048 (2006.01) A61P 29/00 (2006.01)
A61K 31/4355 (2006.01)

(21) International Application Number:

PCT/IB2013/050479

(22) International Filing Date:

18 January 2013 (18.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/IB2012/050282

20 January 2012 (20.01.2012)

IB

(71) Applicant: ACTELION PHARMACEUTICALS LTD
[CH/CH]; Gewerbestrasse 16, CH-4123 Allschwil (CH).

(72) Inventors: HILPERT, Kurt; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). HUBLER, Francis; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). KIMMERLIN, Thierry; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). RENNEBERG, Dorte; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). STAMM, Simon; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(74) Agent: GSCHWEND, Thomas; c/o Actelion Pharmaceuticals Ltd., Legal Department, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))


Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS



(I)

(57) Abstract: The invention relates to heterocyclic amide derivatives of formula (I), wherein R¹, R², R³, X and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Heterocyclic amide derivatives as P2X₇ receptor antagonists

The present invention relates to heterocyclic amide derivatives of formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as P2X₇ receptor antagonists.

The P2X₇ receptors (P2RX7) belong to the family of P2X ionotropic receptors that are activated by extracellular nucleotides, in particular adenosine triphosphate (ATP). P2RX7 is distinguished from other P2X family members by the high concentrations (mM range) of ATP required to activate it and its ability to form a large pore upon prolonged or repeated stimulation (North, R. A., *Physiol. Rev.* 2002, 82(4), 1013-67; Surprenant, A., Rassendren, F. et al., *Science* 1996, 272(5262), 735-8; Virginio, C., MacKenzie, A. et al., *J. Physiol.*, 1999, 519, 335-46). P2RX7 is present on many cell types, especially ones known to be involved in inflammatory and immune processes. This is reflected within both the periphery and the CNS as Lipopolysaccharide S (LPS) priming of monocytes and microglia followed by ATP stimulation has been shown to lead to the local release and processing of IL1 β and other family members including IL18 through a P2RX7 mediated mechanism. Indeed mice lacking the P2X7 receptor are unable to release IL1 β following LPS priming and ATP stimulation providing further evidence of its role in this pathway (Solle, M., Labasi, J. et al., *J. Biol. Chem.*, 2001, 276(1), 125-32). In addition L-selectin shedding from monocytes, macrophages and lymphocytes, degranulation in mast cells and apoptosis in lymphocytes are all associated with P2RX7 stimulation. P2RX7 is also expressed on epithelial and endothelial cells (Ferrari, D., Chiozzi, P. et al., *Neuropharmacology* 1997, 36(9), 1295-301; Wiley, J. S., Chen, J. R. et al., *Ciba Found Symp.* 1996, 198, 149-60 and 160-5; North, R. A., *Physiol. Rev.* 2002, 82(4), 1013-67). In addition to its role in the periphery it may have an important function in neurotransmission within the CNS through its activation on postsynaptic and / or presynaptic central and peripheral neurons and glia (Deuchars, S. A., Atkinson, L. et al., *J. Neurosci.* 2001, 21(18), 7143-52; Sperlagh, B., Kofalvi, A. et al., *J. Neurochem.* 2002, 81(6), 1196-211). Recent data that has emerged using *in situ* hybridization demonstrated that P2X7 receptor mRNA was widely distributed throughout the rat brain. Specifically, among the areas of high P2X7mRNA expression noted were the piriform cortex, hippocampus, pontine nuclei and the anterior horn of the spinal cord (Yu, Y., Ugawa, S. et al., *Brain. Res.* 2008, 1194, 45-55). Hence there is therapeutic rationale for the use of P2X7 ion channel blockers in


the treatment of a variety of disease states. These include but are not limited to diseases associated with the central nervous system such as stroke or injury and diseases associated with neuro-degeneration and neuroinflammation such as Alzheimer's disease, Huntington's disease, epilepsy, Amyotrophic lateral sclerosis, acute spinal cord injury additionally to meningitis, sleep disorders, mood and anxiety disorders as well as chronic and neuropathic and inflammatory pain. Furthermore, peripheral inflammatory disorders and autoimmune diseases including but not limited to rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease, airways hyper-responsiveness, septic shock, bronchitis, glomerulonephritis, irritable bowel disease, skin injury, lung emphysema, Limb girdle dystrophy type 2B, fibrosis, Syndrome of synovitis Acne Pustulosis, atherosclerosis, burn injury, spinal cord injury, Hyperostosis Osteitis, Crohn's disease, ulcerative colitis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, trauma, meningitis, osteoporosis, burn injury, ischemic heart disease, and varicose veins and trauma, are all examples where the involvement of P2X7 channels has been implicated. In addition a recent report suggests a link between P2RX7 and chronic, inflammatory and neuropathic pain (Chessell, I. P., Hatcher, J. P. et al., Pain, 2005, 114(3), 386-96). Overall, these findings indicate a role for the P2X7 receptor in the process of neuronal synaptic transmission and therefore a potential role for P2X7 antagonists as novel therapeutic tools to treat neuropathic pain.

In view of the above observations, there is significant requirement for P2X7 antagonists that can be efficiently used in treating neuropathic pain, chronic inflammatory pain, inflammation, and neurodegenerative conditions.

A different dihydrofuroypyridine derivative, which is also a P2X₇ receptor antagonist, has been disclosed in WO 2005/111003.

Various embodiments of the invention are presented hereafter:

1) The present invention relates to heterocyclic amide derivatives of formula (I),



(I)

wherein

n represents 1 or 2;

X represents -N- or -N(O)-;

R¹ represents hydrogen or halogen (preferably hydrogen or fluorine);

R^2 represents hydrogen or methyl; and

R^3 represents

- aryl-(C_1-C_3)alkyl, which is in the alkyl part optionally mono-substituted with hydroxy or heterocyclyl; and which is in the aryl part mono-, di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C_1-C_4)alkyl, (C_2-C_4)alkenyl, (C_3-C_6)cycloalkyl, (C_1-C_4)alkoxy, hydroxy-(C_1-C_3)alkyl, hydroxy-(C_2-C_3)alkoxy, hydroxy-(C_2-C_3)alkoxy-(C_1-C_2)alkyl, (C_1-C_2)alkoxy-(C_1-C_2)alkyl, (C_1-C_3)fluoroalkyl, (C_1-C_3)fluoroalkoxy, cyano, halogen and phenoxy; or
- heteroaryl-(C_1-C_3)alkyl, which is in the alkyl part mono-substituted with heterocyclyl; and which is in the heteroaryl part mono-, di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C_1-C_4)alkyl, (C_3-C_6)cycloalkyl, (C_1-C_4)alkoxy, (C_1-C_3)fluoroalkyl and halogen; or
- (C_3-C_7)cycloalkyl, which is monosubstituted with $-C(O)NH_2$ or an optionally mono-, di- or tri-substituted phenyl, wherein the substituents are selected from halogen; or
- (C_5-C_7)cycloalkyl, which is optionally mono-substituted with hydroxy or oxo; and which is annelated with an optionally mono-, di- or tri-substituted phenyl, wherein the substituents are selected from halogen; or
- (C_3-C_7)cycloalkyl-(C_1-C_3)alkyl, which is in the alkyl part optionally mono-substituted with hydroxy; and which is in the cycloalkyl part optionally di-substituted with halogen and optionally mono-substituted with hydroxy, aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono-, di- or tri-substituted with halogen;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

The compounds of formula (I) according to embodiment 1) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond may be present in the (*Z*)- or (*E*)-configuration unless indicated otherwise. The compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.

The following paragraphs provide definitions of the various chemical moieties for the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader or narrower definition.

The term "alkyl", used alone or in combination, refers to a straight or branched chain alkyl group containing one to four carbon atoms. The term "(C_x-C_y)alkyl" (x and y each being an integer), refers to an alkyl group as defined before containing x to y carbon atoms. For example a (C₁-C₄)alkyl group contains from one to four carbon atoms. In one embodiment the hydrogen isotopes in any alkyl group may be present according to their natural abundance or one, two or three hydrogen atoms of an alkyl group may be replaced by deuterium atoms. In a preferred embodiment the hydrogen isotopes in any alkyl group may be present according to their natural abundance. Representative examples of alkyl groups include methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *sec*-butyl and *tert*-butyl. Further examples are trideuteromethyl and 2,2,2-trideuteroethyl. The alkyl group may be unsubstituted or substituted as explicitly defined.

In case a (C₁-C₄)alkyl group is a substituent to an aryl group, the term "(C₁-C₄)alkyl" means (C₁-C₄)alkyl groups as defined above. Examples of said groups are methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *sec*-butyl and *tert*-butyl. Further examples are trideuteromethyl and 2,2,2-trideuteroethyl. Preferred are methyl, trideuteromethyl and ethyl. More preferred are methyl and ethyl and most preferred is methyl.

In case a (C₁-C₄)alkyl group is a substituent to a heteroaryl group, the term "(C₁-C₄)alkyl" means (C₁-C₄)alkyl groups as defined above. Examples of said groups are methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *sec*-butyl and *tert*-butyl. Preferred are methyl and ethyl and most preferred is methyl.

The term "aryl-(C_x-C_y)alkyl" (x and y each being an integer) refers to an alkyl group as defined before containing x to y carbon atoms in which one hydrogen atom has been replaced with aryl as defined below. For example an aryl-(C₁-C₃)alkyl group refers to an alkyl group as defined before containing one to three carbon atoms in which one hydrogen atom has been replaced with aryl. Representative examples of aryl-(C₁-C₃)alkyl groups include aryl-methyl, 1-aryl-ethyl, 2-aryl-ethyl, 1-aryl-prop-1-yl, 2-aryl-prop-1-yl, 1-aryl-prop-2-yl, 2-aryl-prop-2-yl and 3-aryl-prop-1-yl. Preferred are aryl-methyl, 1-aryl-ethyl and 2-aryl-ethyl; more preferred are aryl-methyl and 1-aryl-ethyl; and most preferred is aryl-methyl. The alkyl moiety of the aryl-(C₁-C₃)alkyl group may be unsubstituted or substituted as explicitly defined. In case the alkyl moiety is substituted, it is preferred that the nitrogen atom of the amide moiety and a heteroatom of the substituent are not attached to the same carbon atom of the alkyl moiety.

The term "heteroaryl-(C_x-C_y)alkyl" (x and y each being an integer) refers to an alkyl group as defined before containing x to y carbon atoms in which one hydrogen atom has been replaced with heteroaryl as defined below. For example an heteroaryl-(C₁-C₃)alkyl group

refers to an alkyl group as defined before containing one to three carbon atoms in which one hydrogen atom has been replaced with heteroaryl. Representative examples of heteroaryl-(C₁-C₃)alkyl groups include heteroaryl-methyl, 1-heteroaryl-ethyl, 2-heteroaryl-ethyl, 1-heteroaryl-prop-1-yl, 2-heteroaryl-prop-1-yl, 1-heteroaryl-prop-2-yl, 2-heteroaryl-prop-2-yl and 3-heteroaryl-prop-1-yl. Preferred are heteroaryl-methyl, 1-heteroaryl-ethyl and 2-heteroaryl-ethyl; most preferred is 2-heteroaryl-ethyl. The alkyl moiety of the heteroaryl-(C₁-C₃)alkyl group may be unsubstituted or substituted as explicitly defined. In case the alkyl moiety is substituted, it is preferred that the nitrogen atom of the amide moiety and a heteroatom of the substituent are not attached to the same carbon atom of the alkyl moiety.

The term “(C₃-C₇)cycloalkyl-(C_x-C_y)alkyl” (x and y each being an integer) refers to an alkyl group as defined before containing x to y carbon atoms in which one hydrogen atom has been replaced with (C₃-C₇)cycloalkyl as defined below. For example a (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl group refers to an alkyl group as defined before containing one to three carbon atoms in which one hydrogen atom has been replaced with (C₃-C₇)cycloalkyl. Representative examples of (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl groups include (C₃-C₇)cycloalkyl-methyl, 1-(C₃-C₇)cycloalkyl-ethyl, 2-(C₃-C₇)cycloalkyl-ethyl, 1-(C₃-C₇)cycloalkyl-prop-1-yl, 2-(C₃-C₇)cycloalkyl-prop-1-yl, 1-(C₃-C₇)cycloalkyl-prop-2-yl, 2-(C₃-C₇)cycloalkyl-prop-2-yl and 3-(C₃-C₇)cycloalkyl-prop-1-yl. Preferred are (C₃-C₇)cycloalkyl-methyl and 1-(C₃-C₇)cycloalkyl-ethyl; most preferred is (C₃-C₇)cycloalkyl-methyl. The alkyl moiety of the (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl group may be unsubstituted or substituted as explicitly defined. In case the alkyl moiety is substituted, it is preferred that the nitrogen atom of the amide moiety and a heteroatom of the substituent are not attached to the same carbon atom of the alkyl moiety.

The term “hydroxy-(C_x-C_y)alkyl” (x and y each being an integer) refers to an alkyl group as defined before containing x to y carbon atoms in which one hydrogen atom has been replaced with -OH. For example a hydroxy-(C₁-C₃)alkyl group refers to an alkyl group as defined before containing one to three carbon atoms in which one hydrogen atom has been replaced with -OH. Representative examples of hydroxy-(C₁-C₃)alkyl groups include hydroxy-methyl, 1-hydroxy-ethyl, 2-hydroxy-ethyl, 1-hydroxy-propyl, 2-hydroxy-propyl and 3-hydroxy-propyl. Preferred are hydroxy-methyl and 1-hydroxy-ethyl and most preferred is hydroxy-methyl.

The term “hydroxy-(C₂-C₃)alkoxy-(C_x-C_y)alkyl” (x and y each being an integer) refers to an alkyl group as defined before containing x to y carbon atoms in which one hydrogen atom

has been replaced with hydroxy-(C₂-C₃)alkoxy as defined below. For example a hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl group refers to an alkyl group as defined before containing one or two carbon atoms in which one hydrogen atom has been replaced with hydroxy-(C₂-C₃)alkoxy. Representative examples of hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl groups include hydroxy-(C₂-C₃)alkoxy-methyl, 1-[hydroxy-(C₂-C₃)alkoxy]-ethyl and 2-[hydroxy-(C₂-C₃)alkoxy]-ethyl. Preferred is hydroxy-(C₂-C₃)alkoxy-methyl (and especially (2-hydroxy-ethoxy)-methyl).

The term “(C_x-C_y)fluoroalkyl” (x and y each being an integer) refers to an alkyl group as defined before containing x to y carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluoro. For example a (C₁-C₃)fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluoro.

In case “(C₁-C₃)fluoroalkyl” is a substituent to an aryl or a heteroaryl group, the term “(C₁-C₃)fluoroalkyl” means (C₁-C₃)fluoroalkyl groups as defined above. Examples of said groups are difluoromethyl, trifluoromethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl. Preferred is trifluoromethyl.

The term “alkenyl”, used alone or in combination, refers to a straight or branched chain alkenyl group containing two to four carbon atoms. The term “(C_x-C_y)alkenyl” (x and y each being an integer), refers to an alkenyl group as defined before containing x to y carbon atoms. For example a (C₂-C₄)alkenyl group contains from two to four carbon atoms. Representative examples of (C₂-C₄)alkenyl groups include ethenyl, propenyl and butenyl. Preferred is ethenyl.

The term “alkoxy”, used alone or in combination, refers to an alkyl-O- group wherein the alkyl group is as defined above. The term “(C_x-C_y)alkoxy” (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms. For example a (C₁-C₄)alkoxy group contains from one to four carbon atoms. Representative examples of alkoxy groups include methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, *iso*-butoxy, *sec*-butoxy and *tert*-butoxy.

In case a (C₁-C₄)alkoxy group is a substituent to an aryl or a heteroaryl group, the term “(C₁-C₄)alkoxy” means (C₁-C₄)alkoxy groups as defined above. Examples of said groups are methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, *iso*-butoxy, *sec*-butoxy and *tert*-butoxy. Preferred are methoxy and ethoxy; and most preferred is methoxy.

The term “hydroxy-(C_x-C_y)alkoxy” (x and y each being an integer), used alone or in combination, refers to an alkoxy group as defined before containing x to y carbon atoms in

which one hydrogen atom has been replaced with -OH. For example a hydroxy-(C₂-C₃)alkoxy group refers to an alkoxy group as defined before containing two or three carbon atoms in which one hydrogen atom has been replaced with -OH. Representative examples of hydroxy-(C₂-C₃)alkoxy groups include 2-hydroxy-ethoxy, 2-hydroxy-prop-1-oxy, 3-hydroxy-prop-1-oxy and 1-hydroxy-prop-2-oxy. Preferred is 2-hydroxy-ethoxy.

The term "(C₁-C₂)alkoxy-(C₁-C₂)alkyl" refers to an alkyl group as defined before in which one hydrogen atom has been replaced with (C₁-C₂)alkoxy as defined before containing one or two carbon atoms. Representative examples of (C₁-C₂)alkoxy-(C₁-C₂)alkyl groups include methoxy-methyl, ethoxy-methyl, 1-methoxy-ethyl, 2-methoxy-ethyl, 1-ethoxy-ethyl and 2-ethoxy-ethyl. Preferred is methoxy-methyl.

The term "(C_x-C_y)fluoroalkoxy" (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluoro. For example a (C₁-C₃)fluoroalkoxy group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluoro.

In case "(C₁-C₃)fluoroalkoxy" is a substituent to an aryl group, the term "(C₁-C₃)fluoroalkoxy" means (C₁-C₃)fluoroalkoxy groups as defined above. Examples of said groups are difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy and 2,2,2-trifluoroethoxy. Preferred is trifluoromethoxy.

The term "(C_x-C_y)cycloalkyl" (x and y each being an integer), used alone or in combination, means a cycloalkyl group containing x to y carbon atoms. For example a (C₃-C₇)cycloalkyl group contains from 3 to 7 carbon atoms; and a (C₃-C₆)cycloalkyl group contains from 3 to 6 carbon atoms. Examples of (C₃-C₇)cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Examples of (C₃-C₆)cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cycloalkyl group may be unsubstituted or substituted as explicitly defined.

In case a (C₃-C₆)cycloalkyl group is a substituent to an aryl or a heteroaryl group, the term means (C₃-C₆)cycloalkyl groups as defined above. Examples of said groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Preferred is cyclopropyl.

In case "**R**³" represents "(C₃-C₇)cycloalkyl, which is monosubstituted with -C(O)NH₂ or an optionally mono-, di- or tri-substituted phenyl" the term "(C₃-C₇)cycloalkyl" means (C₃-C₇)cycloalkyl groups as defined above. Examples of said groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Preferred are cyclopropyl, cyclopentyl and cyclohexyl. The cycloalkyl group is substituted as explicitly defined.

In case "**R**³" represents "(C₅-C₇)cycloalkyl, which is optionally mono-substituted with hydroxy or oxo; and which is annelated with an optionally mono-, di- or tri-substituted phenyl" the term "(C₅-C₇)cycloalkyl which is annelated with an optionally mono-, di- or tri-substituted phenyl" means a (C₅-C₇)cycloalkyl group as defined above which is annelated with an optionally mono-, di- or tri-substituted phenyl group, wherein the cycloalkyl group and the phenyl group are unsubstituted or substituted as explicitly defined. Examples of said groups are indanyl (preferred), 1,2,3,4-tetrahydronaphthyl or 6,7,8,9-tetrahydro-5H-benzo[7]annulenyl, wherein the cycloalkyl group and the phenyl group are unsubstituted or substituted as explicitly defined. Preferred examples are indan-1-yl, 2-hydroxy-indan-1-yl, 3-oxo-indan-1-yl, 4,6-dichloro-indan-1-yl and 5,7-dichloro-indan-1-yl. Further preferred examples are 5-chloro-indan-1-yl, 7-chloro-indan-1-yl, 7-bromo-indan-1-yl, 5,7-dichloro-1-oxo-indan-2-yl, 1,2,3,4-tetrahydronaphthalen-1-yl and 8-chloro-1,2,3,4-tetrahydronaphthalen-1-yl. Most preferred is 5,7-dichloro-indan-1-yl. In case the (C₅-C₇)cycloalkyl moiety is substituted with hydroxy, it is preferred that the nitrogen atom of the amide moiety and the substituent are not attached to the same carbon atom of the (C₅-C₇)cycloalkyl moiety.

In case "**R**³" represents "(C₃-C₇)cycloalkyl-(C₁-C₃)alkyl" the term "(C₃-C₇)cycloalkyl" means (C₃-C₇)cycloalkyl groups as defined above. Examples of said groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Preferred are cyclohexyl and cycloheptyl. The cycloalkyl group is unsubstituted or substituted as explicitly defined.

The term halogen means fluoro, chloro, bromo or iodo, preferably fluoro, chloro or bromo.

In case "**R**¹" represents "halogen" the term means preferably fluoro, chloro or bromo; more preferably fluoro or chloro; and most preferably fluoro.

In case "halogen" is a substituent to an aryl, a phenyl or a heteroaryl group, the term "halogen" means fluoro, chloro, bromo or iodo; preferably fluoro, chloro or bromo; more preferably chloro or bromo; and most preferably chloro.

In case "halogen" is a substituent to a cycloalkyl or heterocyclyl group, the term "halogen" means fluoro, chloro, bromo or iodo; preferably fluoro or chloro; and most preferably fluoro.

The term "aryl", used alone or in any combination, means a phenyl or a naphthyl group. Preferred is a phenyl group. The aryl group is unsubstituted or substituted as explicitly defined.

In case "**R**³" represents "aryl-(C₁-C₃)alkyl", the term "aryl" means phenyl or naphthyl. Preferred is a phenyl group. The aryl group is unsubstituted or substituted as explicitly defined. Examples are 4-chloro-phenyl, 2,3-dichloro-phenyl, 2,4-dichloro-phenyl, 2,4-

dichloro-6-fluoro-phenyl, 2-chloro-4-fluoro-phenyl, 2-bromo-4,6-dichloro-phenyl, 3-chloro-2-methyl-phenyl, 2,4-dichloro-6-methyl-phenyl, 2,4-dichloro-6-ethyl-phenyl, 2,4-dichloro-6-cyclopropyl-phenyl, 2,4-dichloro-6-vinyl-phenyl, 2,4-dichloro-6-hydroxymethyl-phenyl, 2,4-dichloro-6-methoxy-phenyl, 2,4-dichloro-6-methoxymethyl-phenyl, 2,4-dichloro-6-(2-hydroxy-ethoxy)-phenyl, 2,4-dichloro-6-(2-hydroxy-ethoxymethyl)-phenyl, 2-chloro-3-trifluoromethyl-phenyl, 3-chloro-2-trifluoromethyl-phenyl, 2,4-dichloro-6-trifluoromethyl-phenyl, 3-fluoro-4-trifluoromethoxy-phenyl, 2-chloro-3-cyano-phenyl, 2-chloro-4-cyano-phenyl, 4-trifluoromethyl-phenyl and 4-phenoxy-phenyl. Further examples are 2,4,6-trichloro-phenyl, 2,4-dichloro-6-trideuteromethyl-phenyl, 2-chloro-6-hydroxymethyl-phenyl, 4-chloro-2-hydroxymethyl-phenyl and 2-chloro-4-trifluoromethyl-phenyl. Preferred examples are 2,3-dichloro-phenyl, 2,4-dichloro-phenyl, 2-bromo-4,6-dichloro-phenyl, 3-chloro-2-methyl-phenyl, 2,4-dichloro-6-methyl-phenyl, 2,4-dichloro-6-ethyl-phenyl, 2,4-dichloro-6-cyclopropyl-phenyl, 2,4-dichloro-6-vinyl-phenyl, 2,4-dichloro-6-hydroxymethyl-phenyl, 2,4-dichloro-6-methoxymethyl-phenyl, 2,4-dichloro-6-(2-hydroxy-ethoxymethyl)-phenyl, 2-chloro-3-trifluoromethyl-phenyl and 2,4-dichloro-6-trifluoromethyl-phenyl.

In case "aryl" is a substituent to a (C₃–C₇)cycloalkyl-(C₁–C₃)alkyl group, the term "aryl" means phenyl or naphthyl. Preferred is a phenyl group. The aryl group is unsubstituted or substituted as explicitly defined. A preferred example is phenyl.

The term "heteroaryl", used alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur. Preferred is a 5- or 6-membered monocyclic aromatic ring containing 1, 2 or 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from oxygen, nitrogen and sulphur (preferably from oxygen and nitrogen). Most preferred is a 6-membered monocyclic aromatic ring containing 1 or 2 nitrogen atoms. Examples of such heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl and phthalazinyl. Preferred examples are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl. The heteroaryl group is unsubstituted or substituted as explicitly defined.

In case " R^3 " represents "heteroaryl-(C_1 - C_3)alkyl", the term "heteroaryl" means a heteroaryl group as defined above. Preferred is a 5- or 6-membered monocyclic aromatic ring containing 1, 2 or 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from oxygen, nitrogen and sulphur (preferably from oxygen and nitrogen). Most preferred is a 6-membered monocyclic aromatic ring containing 1 or 2 nitrogen atoms. Preferred examples are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl. Most preferred examples are pyridyl (notably pyridin-3-yl) and pyrimidyl (notably pyrimidin-5-yl). The heteroaryl group is unsubstituted or substituted as explicitly defined.

Preferred examples of unsubstituted or substituted heteroaryl groups are 2-chloro-pyridin-5-yl, 2-methyl-pyridin-5-yl, 2-methoxy-pyridin-5-yl, 2-trifluoromethyl-pyridin-5-yl, 2-methyl-pyrimidin-5-yl, 2-cyclopropyl-pyrimidin-5-yl and 2-trifluoromethyl-pyrimidin-5-yl. Most preferred are 2-chloro-pyridin-5-yl and 2-trifluoromethyl-pyrimidin-5-yl.

In case "heteroaryl" is a substituent to a (C_3 - C_7)cycloalkyl-(C_1 - C_3)alkyl group, the term "heteroaryl" means a heteroaryl group as defined above. Preferred is a 5- or 6-membered monocyclic aromatic ring containing 1, 2 or 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from oxygen, nitrogen and sulphur (preferably from oxygen and nitrogen). Most preferred is a 6-membered monocyclic aromatic ring containing 1 or 2 nitrogen atoms. Preferred examples are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl. More preferred examples are pyridyl (notably pyridin-3-yl) and pyrimidyl (notably pyrimidin-5-yl); most preferred is pyridyl (notably pyridin-3-yl). The heteroaryl group is unsubstituted or substituted as explicitly defined. A preferred example of an unsubstituted or substituted heteroaryl group is 2-chloro-pyridin-5-yl.

The term "heterocyclyl", used alone or in combination, refers to a saturated monocyclic moiety of 5 to 7 ring members containing 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur, it being understood that a heterocyclyl group does not contain 2 sulfur atoms. The sulfur atom of a heterocyclyl group may be in an oxidised form, i.e. as a sulfoxide or sulfonyl. Preferred is a saturated monocyclic moiety of 5 or 6 ring members (especially 6 ring members) containing 1 or 2 heteroatoms selected from nitrogen and oxygen. The heterocyclyl group is unsubstituted or substituted as explicitly defined.

In case "heterocyclyl" is a substituent to an aryl-(C_1 - C_3)alkyl group, the term "heterocyclyl" means a heterocyclyl group as defined above. Preferred is a saturated monocyclic moiety of 5 or 6 ring members (especially 6 ring members) containing 1 or 2 heteroatoms selected from nitrogen and oxygen. Examples of such heterocyclyl groups are pyrrolidinyl,

imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and dioxanyl. Preferred examples are piperidinyl (notably piperidin-1-yl) and morpholinyl (notably morpholin-4-yl); most preferred is piperidinyl (notably piperidin-1-yl). The heterocyclyl group is unsubstituted or mono- or di-substituted with halogen (notably fluorine). An example of an unsubstituted or mono- or di-substituted heterocyclyl group is 4,4-difluoro-piperidin-1-yl.

In case "heterocyclyl" is a substituent to a heteroaryl-(C₁-C₃)alkyl group, the term "heterocyclyl" means a heterocyclyl group as defined above. Preferred is a saturated monocyclic moiety of 5 or 6 ring members (especially 6 ring members) containing 1 or 2 heteroatoms selected from nitrogen and oxygen. Examples of such heterocyclyl groups are pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and dioxanyl. Preferred examples are piperidinyl (notably piperidin-1-yl) and morpholinyl (notably morpholin-4-yl). The heterocyclyl group is unsubstituted or mono- or di-substituted with halogen (notably fluorine). Examples of unsubstituted or mono- or di-substituted heterocyclyl groups are 4,4-difluoro-piperidin-1-yl and morpholin-4-yl.

2) A further embodiment of the invention relates to compounds according to embodiment 1), wherein

n represents 1 or 2;

X represents -N- or -N(O)-;

R¹ represents hydrogen or fluorine;

R² represents hydrogen; and

R³ represents

- aryl-(C₁-C₂)alkyl, which is in the aryl part mono-, di- or tri-substituted (preferably di- or tri-substituted), wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, hydroxy-(C₁-C₃)alkyl, hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl, (C₁-C₂)alkoxy-(C₁-C₂)alkyl, (C₁-C₃)fluoroalkyl and halogen; or
- heteroaryl-(C₁-C₂)alkyl (preferably 2-heteroaryl-ethyl), which is in the alkyl part mono-substituted with heterocyclyl; and which is in the heteroaryl part mono- or di-substituted (preferably mono-substituted), wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₁-C₃)fluoroalkyl and halogen (preferably from (C₁-C₃)fluoroalkyl and halogen); or

- (C₅–C₇)cycloalkyl, which is annelated with an optionally mono-, di- or tri-substituted (preferably mono- or di-substituted) phenyl, wherein the substituents are selected from halogen; or
- (C₅–C₇)cycloalkyl-(C₁–C₂)alkyl, which is in the cycloalkyl part optionally di-substituted with halogen (preferably fluorine) and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono- or di-substituted with halogen;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

3) A further embodiment of the invention relates to compounds according to embodiment 1), wherein

n represents 1 or 2;

X represents -N- or -N(O)-;

R¹ represents hydrogen or fluorine;

R² represents hydrogen; and

R³ represents

- aryl-methyl, which is in the aryl part di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁–C₄)alkyl, (C₂–C₄)alkenyl, (C₃–C₆)cycloalkyl, (C₁–C₄)alkoxy, hydroxy-(C₁–C₃)alkyl, hydroxy-(C₂–C₃)alkoxy-(C₁–C₂)alkyl, (C₁–C₂)alkoxy-(C₁–C₂)alkyl, (C₁–C₃)fluoroalkyl and halogen (and preferably from methyl, ethyl, cyclopropyl, trifluoromethyl, fluoro, chloro and bromo); or
- cyclopentyl, which is annelated with a mono- or di-substituted phenyl, wherein the substituents are selected from halogen; or
- cyclohexyl-methyl, which is in the cyclohexyl part optionally di-substituted with fluorine and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono- or di-substituted with halogen;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

4) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 3), wherein

n represents 1;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

5) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 3), wherein

n represents 2;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

6) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 5), wherein

X represents -N-;

5 and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

7) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), wherein

R¹ represents hydrogen;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

10 8) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), wherein

R¹ represents fluorine;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

15 9) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 8), wherein

R² represents hydrogen;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

10) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 2) or 4) to 9), wherein

20 **R**³ represents

- aryl-(C₁-C₂)alkyl, which is in the aryl part mono-, di- or tri-substituted (preferably di- or tri-substituted), wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, hydroxy-(C₁-C₃)alkyl, hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl, (C₁-C₂)alkoxy-(C₁-C₂)alkyl, (C₁-C₃)fluoroalkyl and halogen; or
- (C₅-C₇)cycloalkyl, which is annelated with an optionally mono-, di- or tri-substituted (preferably mono- or di-substituted) phenyl, wherein the substituents are selected from halogen; or
- (C₅-C₇)cycloalkyl-(C₁-C₂)alkyl, which is in the cycloalkyl part optionally di-substituted with halogen (preferably fluorine) and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono- or di-substituted with halogen;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

11) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 2) or 4) to 9), wherein

R³ represents

- (C₅–C₇)cycloalkyl, which is annelated with an optionally mono-, di- or tri-substituted (preferably mono- or di-substituted) phenyl, wherein the substituents are selected from halogen; or
- (C₅–C₇)cycloalkyl-(C₁–C₂)alkyl, which is in the cycloalkyl part optionally di-substituted with halogen (preferably fluorine) and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono- or di-substituted with halogen;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

12) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 9), wherein

R³ represents

- aryl-methyl, which is in the aryl part di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁–C₄)alkyl, (C₂–C₄)alkenyl, (C₃–C₆)cycloalkyl, (C₁–C₄)alkoxy, hydroxy-(C₁–C₃)alkyl, hydroxy-(C₂–C₃)alkoxy-(C₁–C₂)alkyl, (C₁–C₂)alkoxy-(C₁–C₂)alkyl, (C₁–C₃)fluoroalkyl and halogen (and preferably from methyl, ethyl, cyclopropyl, trifluoromethyl, fluoro, chloro and bromo); or
- cyclopentyl, which is annelated with an mono- or di-substituted phenyl, wherein the substituents are selected from halogen; or
- cyclohexyl-methyl, which is in the cyclohexyl part optionally di-substituted with fluorine and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono- or di-substituted with halogen;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

13) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 9), wherein

R³ represents

- cyclopentyl, which is annelated with an mono- or di-substituted phenyl, wherein the substituents are selected from halogen; or
- cyclohexyl-methyl, which is in the cyclohexyl part optionally di-substituted with fluorine and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono- or di-substituted with halogen;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

14) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 4) to 9), wherein

5 R^3 represents aryl-(C₁-C₃)alkyl (preferably aryl-(C₁-C₂)alkyl), which is in the alkyl part optionally mono-substituted with hydroxy or heterocyclyl; and which is in the aryl part mono-, di- or tri-substituted (preferably di- or tri-substituted), wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, hydroxy-(C₁-C₃)alkyl, hydroxy-(C₂-C₃)alkoxy, hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl, (C₁-C₂)alkoxy-(C₁-C₂)alkyl, (C₁-C₃)fluoroalkyl, (C₁-C₃)fluoroalkoxy, cyano, halogen and phenoxy (and preferably from (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, hydroxy-(C₁-C₃)alkyl, hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl, (C₁-C₂)alkoxy-(C₁-C₂)alkyl, (C₁-C₃)fluoroalkyl and halogen);

10 and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

15) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 9), wherein

15 R^3 represents aryl-(C₁-C₂)alkyl (preferably aryl-methyl), which is in the aryl part di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, hydroxy-(C₁-C₃)alkyl, hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl, (C₁-C₂)alkoxy-(C₁-C₂)alkyl, (C₁-C₃)fluoroalkyl and halogen (and preferably from methyl, ethyl, cyclopropyl, trifluoromethyl, fluoro, chloro and bromo);

20 and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

16) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 4) to 9), wherein

25 R^3 represents heteroaryl-(C₁-C₃)alkyl, which is in the alkyl part mono-substituted with heterocyclyl; and which is in the heteroaryl part mono-, di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, (C₁-C₃)fluoroalkyl and halogen (preferably from (C₁-C₃)fluoroalkyl and halogen);

30 and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

17) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 2) or 4) to 9), wherein

R^3 represents heteroaryl-(C₁-C₂)alkyl (preferably 2-heteroaryl-ethyl), which is in the alkyl part mono-substituted with heterocyclyl; and which is in the heteroaryl part mono- or di-

substituted (preferably mono-substituted), wherein the substituents are independently selected from the group consisting of (C₁–C₄)alkyl, (C₁–C₃)fluoroalkyl and halogen (preferably from (C₁–C₃)fluoroalkyl and halogen);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

- 5 18) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 4) to 9), wherein

R³ represents (C₅–C₇)cycloalkyl, which is optionally mono-substituted with hydroxy or oxo; and which is annelated with an optionally mono-, di- or tri-substituted phenyl, wherein the substituents are selected from halogen;

- 10 and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

19) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 9), wherein

R³ represents (C₅–C₆)cycloalkyl (preferably cyclopentyl), which is annelated with an mono- or di-substituted phenyl, wherein the substituents are selected from halogen;

- 15 and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

20) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 4) to 9), wherein

R³ represents (C₃–C₇)cycloalkyl-(C₁–C₃)alkyl, which is in the alkyl part optionally mono-substituted with hydroxy; and which is in the cycloalkyl part optionally di-substituted with halogen and optionally mono-substituted with hydroxy, aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono-, di- or tri- substituted with halogen;


- 20 and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

21) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 9), wherein

- 25 **R**³ represents (C₅–C₇)cycloalkyl-(C₁–C₂)alkyl (preferably cyclohexyl-methyl), which is in the cycloalkyl part optionally di-substituted with fluorine and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono- or di- substituted with halogen;


and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

- 30 22) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 21), wherein the absolute configuration of the stereogenic center is as depicted in formula (I_{St1})



and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

23) A further embodiment of the invention relates to compounds according to any one of
5 embodiments 1) to 21), wherein the absolute configuration of the stereogenic center is as
depicted in formula (I_{Sl2})



and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

10 24) Preferred compounds of formula (I) as defined in embodiment 1) are selected from the group consisting of:

(S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide;

(R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-
15 amide;

(S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;

(R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;

2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-benzylamide;

(S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-
20 hydroxy-ethyl]-amide;

(R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide;

3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid ((*S*)-1-cyclohexyl-2-hydroxy-ethyl)-amide;

25 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid [(*S*)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide;

3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (1-hydroxy-cyclohexylmethyl)-amide:

30 3-Fluoro-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-
benzylamide;

- 4-Fluoro-3,4-dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;
(*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*S*^{*})-1-cycloheptyl-2-hydroxy-ethyl)-amide;
- 5 (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*R*^{*})-1-cycloheptyl-2-hydroxy-ethyl)-amide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-fluoro-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide;
(*S*)-3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-
- 10 benzylamide;
(*R*)-3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid [1-(6-chloro-pyridin-3-yl)-cyclohexylmethyl]-amide;
- 15 3-Fluoro-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,3-dichloro-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-cyclopropyl-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-ethyl-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-vinyl-benzylamide;
(*S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-hydroxymethyl-
- 20 benzylamide;
(*R*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-hydroxymethyl-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methoxy-benzylamide;
(*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*S*^{*})-2-(4,4-difluoro-piperidin-1-yl)-2-
- 25 (2-methyl-pyrimidin-5-yl)-ethyl]-amide;
(*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*R*^{*})-2-(4,4-difluoro-piperidin-1-yl)-2-(2-methyl-pyrimidin-5-yl)-ethyl]-amide;
(*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*S*^{*})-2-(2-methyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide;
- 30 (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*R*^{*})-2-(2-methyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 3-chloro-2-methyl-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2-chloro-4-fluoro-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 4-phenoxy-benzylamide;
- 35 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,3-dichloro-benzylamide;

- 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 4-chloro-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 4-trifluoromethyl-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (4-chloro-benzyl)-methyl-amide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-
5 amide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2-chloro-3-trifluoromethyl-
benzylamide;
8-Oxy-3,4-dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-
10 benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 3-chloro-2-methyl-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-4-fluoro-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 4-phenoxy-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,3-dichloro-benzylamide;
15 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 4-chloro-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 4-trifluoromethyl-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (4-chloro-benzyl)-methyl-amide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-(2-hydroxy-ethoxy)-
20 benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-hydroxymethyl-
benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-
amide;
25 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 3-fluoro-4-trifluoromethoxy-
benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (1-phenyl-cyclohexylmethyl)-
amide;
3-Fluoro-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-3-trifluoromethyl-
30 benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-3-cyano-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 3-fluoro-4-trifluoromethoxy-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid [1-(2,4-dichloro-phenyl)-
cyclopropyl]-amide;

- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S*)-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(R*)-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- 5 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-4-cyano-benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (1-carbamoyl-cyclopentyl)-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (2-phenyl-cyclopropyl)-amide;
- 10 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((1S,2R)-2-hydroxy-indan-1-yl)-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (2-carbamoyl-cyclohexyl)-amide;
- 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (1-(6-chloropyridin-3-yl)-4,4-difluorocyclohexylmethyl)-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-trifluoromethyl-
- 15 benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (R)-indan-1-ylamide;
- (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(R)-1-(2,4-dichloro-phenyl)-ethyl]-amide;
- (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(R)-1-(2,4-dichloro-phenyl)-ethyl]-
- 20 amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methoxymethyl-benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 3-chloro-2-trifluoromethyl-benzylamide;
- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S*)-2-(6-chloro-pyridin-3-yl)-2-(4,4-
- 25 difluoro-piperidin-1-yl)-ethyl]-amide;
- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(R*)-2-(6-chloro-pyridin-3-yl)-2-(4,4-difluoro-piperidin-1-yl)-ethyl]-amide;
- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S*)-5,7-dichloro-indan-1-yl)-amide;
- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R*)-5,7-dichloro-indan-1-yl)-amide;
- 30 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(4-trifluoromethyl-phenyl)-ethyl]-amide;
- (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-bromo-4,6-dichloro-benzylamide;
- (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-bromo-4,6-dichloro-benzylamide;
- (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S)-2-morpholin-4-yl-2-(2-
- 35 trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;

- (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(R)-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S)-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- 5 (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(R)-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(6-methoxy-pyridin-3-yl)-2-morpholin-4-yl-ethyl]-amide;
- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S*)-3-oxo-indan-1-yl)-amide;
- 10 (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R*)-3-oxo-indan-1-yl)-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(6-methyl-pyridin-3-yl)-2-morpholin-4-yl-ethyl]-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(2-cyclopropyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide;
- 15 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-(2-hydroxy-ethoxymethyl)-benzylamide;
- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S*)-4,6-dichloro-indan-1-yl)-amide;
- 20 and
- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R*)-4,6-dichloro-indan-1-yl)-amide;
- or salts (in particular pharmaceutically acceptable salts) of such compounds;
- it is to be understood for any of the above listed compounds, that a stereogenic center, which is not specifically assigned, may be in absolute (*R*)- or absolute (*S*)-configuration;
- 25 for example, the stereogenic center at the 3-position of the 2,3-dihydro-furo[2,3-*b*]pyridine core structure or at the 4-position of the 3,4-dihydro-2H-pyrano[2,3-*b*]pyridine core structure may be in absolute (*R*)-configuration or absolute (*S*)-configuration. For example a compound listed as 3,4-dihydro-2H-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide may be (S)-3,4-dihydro-2H-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide, (R)-3,4-dihydro-2H-pyrano[2,3-*b*]pyridine-4-
- 30 carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide or any mixture thereof; and a compound listed as 3,4-dihydro-2H-pyrano[2,3-*b*]pyridine-4-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide may be (S)-3,4-dihydro-2H-pyrano[2,3-*b*]pyridine-4-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide, (R)-3,4-dihydro-2H-pyrano[2,3-*b*]pyridine-4-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-
- 35

amide or any mixture thereof. Notably, compounds containing more than one stereogenic center may be at each stereogenic center, which is not specifically assigned, in absolute (*R*)- or absolute (*S*)-configuration; for example a compound listed as 2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide may be (*S*)-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*S*)-2-(4,4-difluoro-piperidin-1-yl)-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide, (*S*)-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*R*)-2-(4,4-difluoro-piperidin-1-yl)-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide, (*R*)-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*S*)-2-(4,4-difluoro-piperidin-1-yl)-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide, (*R*)-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*R*)-2-(4,4-difluoro-piperidin-1-yl)-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide or any mixture thereof. The assignment of two stereocenters relative to each other is marked by an asterisk; for example a compound listed as (*S*^{*})-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*S*^{*})-1-cycloheptyl-2-hydroxy-ethyl)-amide may be (*S*)-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*S*)-1-cycloheptyl-2-hydroxy-ethyl)-amide, (*R*)-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*R*)-1-cycloheptyl-2-hydroxy-ethyl)-amide or any mixture thereof.

25) Further preferred compounds of formula (I) as defined in embodiment 1) are selected from the group consisting of:

(*S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-trideuteromethyl-benzylamide;

(*R*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-trideuteromethyl-benzylamide;

(*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*S*^{*})-5-chloro-indan-1-yl)-amide;

(*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*R*^{*})-5-chloro-indan-1-yl)-amide;

(*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*S*^{*})-7-chloro-indan-1-yl)-amide;

(*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*R*^{*})-7-chloro-indan-1-yl)-amide;

2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-4-trifluoromethyl-benzylamide;

2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide;

2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [3-(2,4-dichloro-phenyl)-propyl]-amide;

(*S*)-2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid ((*R*)-1,2,3,4-tetrahydronaphthalen-1-yl)-amide;

(*R*)-2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid ((*R*)-1,2,3,4-tetrahydronaphthalen-1-yl)-amide;

2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide;

(S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R)-8-chloro-1,2,3,4-tetrahydro-naphthalen-1-yl)-amide;

(R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R)-8-chloro-1,2,3,4-tetrahydro-naphthalen-1-yl)-amide;

5 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (7-bromo-indan-1-yl)-amide;

2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4,6-trichloro-benzylamide;

7-Oxy-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;

2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (5,7-dichloro-1-oxo-indan-2-yl)-amide;

10 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 4-chloro-2-hydroxymethyl-benzylamide;
and

2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-6-hydroxymethyl-benzylamide;
or salts (in particular pharmaceutically acceptable salts) of such compounds;

it is to be understood for any of the above listed compounds, that a stereogenic center,

15 which is not specifically assigned, may be in absolute (*R*)- or absolute (*S*)-configuration;
for example, the stereogenic center at the 3-position of the 2,3-dihydro-furo[2,3-*b*]pyridine
core structure or at the 4-position of the 3,4-dihydro-2H-pyrano[2,3-*b*]pyridine core
structure may be in absolute (*R*)-configuration or absolute (*S*)-configuration. For example

a compound listed as 2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4,6-trichloro-
20 benzylamide may be (S)-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4,6-trichloro-
benzylamide, (R)-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4,6-trichloro-
benzylamide or any mixture thereof. Notably, compounds containing more than one
stereogenic center may be at each stereogenic center, which is not specifically assigned,

in absolute (*R*)- or absolute (*S*)-configuration; for example a compound listed as 2,3-
25 dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (7-bromo-indan-1-yl)-amide may be (S)-2,3-
dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S)-7-bromo-indan-1-yl)-amide, (S)-2,3-
dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R)-7-bromo-indan-1-yl)-amide, (R)-2,3-
dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S)-7-bromo-indan-1-yl)-amide, (R)-2,3-
dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R)-7-bromo-indan-1-yl)-amide or any

30 mixture thereof. The assignment of two stereocenters relative to each other is marked by
an asterisk; for example a compound listed as (S*)-2,3-dihydro-furo[2,3-*b*]pyridine-3-
carboxylic acid ((S*)-5-chloro-indan-1-yl)-amide may be (S)-2,3-dihydro-furo[2,3-
b]pyridine-3-carboxylic acid ((S)-5-chloro-indan-1-yl)-amide, (R)-2,3-Dihydro-furo[2,3-
b]pyridine-3-carboxylic acid ((R)-5-chloro-indan-1-yl)-amide or any mixture thereof.

It is well understood that the invention relates to compounds according to embodiment 1); or according to embodiment 1) limited by the features of an embodiment dependent on embodiment 1; or according to embodiment 1) limited by the features of a cascade of dependent embodiments e.g. in the form of “embodiment 3) depending on embodiment 2) depending on embodiment 1)”. In case of an embodiment depending on more than one other embodiment, it is understood that each combination is specifically disclosed. Also, in case an embodiment is dependent on more than one other embodiment and one or more of said other embodiments are themselves dependent on one or more further embodiments, it is understood that each combination is specifically disclosed if obtainable with regard to the given dependencies and multiple dependencies. Notably, embodiments resulting from cascades of more than three embodiments depending on each other may be construed under observance of the given dependencies and multiple dependencies and are thus intended to be specifically disclosed. Representative examples of embodiments which are possible based on the dependencies of the embodiments 1) to 25) as disclosed hereinabove and which are therefore intended and herewith specifically disclosed in individualized form are:

1, 2+1, 3+1, 4+1, 4+3+1, 5+1, 5+3+1, 6+1, 6+3+1, 7+1, 7+3+1, 8+1, 8+3+1, 9+1, 9+3+1, 9+7+1, 9+7+3+1, 9+8+1, 9+8+3+1, 10+1, 10+7+1, 10+7+3+1, 10+8+1, 10+8+3+1, 10+9+1, 10+9+3+1, 10+9+7+1, 10+9+7+3+1, 10+9+8+1, 10+9+8+3+1, 11+1, 11+7+1, 11+7+3+1, 11+8+1, 11+8+3+1, 11+9+1, 11+9+3+1, 11+9+7+1, 11+9+7+3+1, 11+9+8+1, 11+9+8+3+1, 12+1, 12+3+1, 12+7+1, 12+7+3+1, 12+8+1, 12+8+3+1, 12+9+1, 12+9+3+1, 12+9+7+1, 12+9+7+3+1, 12+9+8+1, 12+9+8+3+1, 13+1, 13+3+1, 13+7+1, 13+7+3+1, 13+8+1, 13+8+3+1, 13+9+1, 13+9+3+1, 13+9+7+1, 13+9+7+3+1, 13+9+8+1, 13+9+8+3+1, 14+1, 14+7+1, 14+7+3+1, 14+8+1, 14+8+3+1, 14+9+1, 14+9+3+1, 14+9+7+1, 14+9+7+3+1, 14+9+8+1, 14+9+8+3+1, 15+1, 15+3+1, 15+7+1, 15+7+3+1, 15+8+1, 15+8+3+1, 15+9+1, 15+9+3+1, 15+9+7+1, 15+9+7+3+1, 15+9+8+1, 15+9+8+3+1, 16+1, 16+7+1, 16+7+3+1, 16+8+1, 16+8+3+1, 16+9+1, 16+9+3+1, 16+9+7+1, 16+9+7+3+1, 16+9+8+1, 16+9+8+3+1, 17+1, 17+7+1, 17+7+3+1, 17+8+1, 17+8+3+1, 17+9+1, 17+9+3+1, 17+9+7+1, 17+9+7+3+1, 17+9+8+1, 17+9+8+3+1, 18+1, 18+7+1, 18+7+3+1, 18+8+1, 18+8+3+1, 18+9+1, 18+9+3+1, 18+9+7+1, 18+9+7+3+1, 18+9+8+1, 18+9+8+3+1, 19+1, 19+3+1, 19+7+1, 19+7+3+1, 19+8+1, 19+8+3+1, 19+9+1, 19+9+3+1, 19+9+7+1, 19+9+7+3+1, 19+9+8+1, 19+9+8+3+1, 20+1, 20+7+1, 20+7+3+1, 20+8+1, 20+8+3+1, 20+9+1, 20+9+3+1, 20+9+7+1, 20+9+7+3+1, 20+9+8+1, 20+9+8+3+1, 21+1, 21+3+1, 21+7+1, 21+7+3+1, 21+8+1, 21+8+3+1, 21+9+1, 21+9+3+1, 21+9+7+1, 21+9+7+3+1, 21+9+8+1, 21+9+8+3+1, 22+1, 22+3+1, 22+7+1, 22+7+3+1,

22+8+1, 22+8+3+1, 22+9+1, 22+9+3+1, 22+9+7+1, 22+9+7+3+1, 22+9+8+1,
22+9+8+3+1, 22+10+1, 22+10+7+1, 22+10+7+3+1, 22+10+8+1, 22+10+8+3+1,
22+10+9+1, 22+10+9+3+1, 22+10+9+7+1, 22+10+9+7+3+1, 22+10+9+8+1,
22+10+9+8+3+1, 22+15+1, 22+15+3+1, 22+15+7+1, 22+15+7+3+1, 22+15+8+1,
5 22+15+8+3+1, 22+15+9+1, 22+15+9+3+1, 22+15+9+7+1, 22+15+9+7+3+1,
22+15+9+8+1, 22+15+9+8+3+1, 22+17+1, 22+17+7+1, 22+17+7+3+1, 22+17+8+1,
22+17+8+3+1, 22+17+9+1, 22+17+9+3+1, 22+17+9+7+1, 22+17+9+7+3+1,
22+17+9+8+1, 22+17+9+8+3+1, 22+19+1, 22+19+3+1, 22+19+7+1, 22+19+7+3+1,
22+19+8+1, 22+19+8+3+1, 22+19+9+1, 22+19+9+3+1, 22+19+9+7+1, 22+19+9+7+3+1,
10 22+19+9+8+1, 22+19+9+8+3+1, 22+21+1, 22+21+3+1, 22+21+7+1, 22+21+7+3+1,
22+21+8+1, 22+21+8+3+1, 22+21+9+1, 22+21+9+3+1, 22+21+9+7+1, 22+21+9+7+3+1,
22+21+9+8+1, 22+21+9+8+3+1, 23+1, 23+3+1, 23+7+1, 23+7+3+1, 23+8+1, 23+8+3+1,
23+9+1, 23+9+3+1, 23+9+7+1, 23+9+7+3+1, 23+9+8+1, 23+9+8+3+1, 23+10+1,
23+10+7+1, 23+10+7+3+1, 23+10+8+1, 23+10+8+3+1, 23+10+9+1, 23+10+9+3+1,
15 23+10+9+7+1, 23+10+9+7+3+1, 23+10+9+8+1, 23+10+9+8+3+1, 23+15+1, 23+15+3+1,
23+15+7+1, 23+15+7+3+1, 23+15+8+1, 23+15+8+3+1, 23+15+9+1, 23+15+9+3+1,
23+15+9+7+1, 23+15+9+7+3+1, 23+15+9+8+1, 23+15+9+8+3+1, 23+17+1, 23+17+7+1,
23+17+7+3+1, 23+17+8+1, 23+17+8+3+1, 23+17+9+1, 23+17+9+3+1, 23+17+9+7+1,
23+17+9+7+3+1, 23+17+9+8+1, 23+17+9+8+3+1, 23+19+1, 23+19+3+1, 23+19+7+1,
20 23+19+7+3+1, 23+19+8+1, 23+19+8+3+1, 23+19+9+1, 23+19+9+3+1, 23+19+9+7+1,
23+19+9+7+3+1, 23+19+9+8+1, 23+19+9+8+3+1, 23+21+1, 23+21+3+1, 23+21+7+1,
23+21+7+3+1, 23+21+8+1, 23+21+8+3+1, 23+21+9+1, 23+21+9+3+1, 23+21+9+7+1,
23+21+9+7+3+1, 23+21+9+8+1, 23+21+9+8+3+1, 24+1, and 25+1;

wherein the list above is not to be construed as limiting with respect to further
25 embodiments which are also possible based on the dependencies of the embodiments 1)
to 25) as disclosed hereinabove and which are also intended. In the list above the
numbers refer to the embodiments according to their numbering provided hereinabove
whereas "+" indicates the dependency from another embodiment. The different
individualized embodiments are separated by commas. In other words, "4+3+1" for
30 example refers to embodiment 4) depending on embodiment 3) depending on
embodiment 1), i.e. embodiment "4+3+1" corresponds to embodiment 1) further limited by
the features of embodiments 3) and 4).

The present invention also includes isotopically labelled, especially ^2H (deuterium)
labelled compounds of formula (I), which compounds are identical to the compounds of
35 formula (I) except that one or more atoms have each been replaced by an atom having

the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially ^2H (deuterium) labelled compounds of formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope ^2H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased *in-vivo* half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labelled at all. Isotopically labelled compounds of formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.

The term "pharmaceutically acceptable salts" refers to non-toxic, inorganic or organic acid and/or base addition salts, Lit. e.g. "Salt selection for basic drugs", *Int. J. Pharm.* (1986), **33**, 201-217.

Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, pharmaceutical composition, disease or the like.

The compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for use as medicaments. In particular, compounds of formula (I) modulate the P2X_7 receptor, i.e. they act as P2X_7 receptor antagonists, and are useful for the prevention or treatment of diseases which are associated with the activation of the P2X_7 receptor such as pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.

In particular, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of pain. Pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and

dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain.

- 5 Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, post-herpetic neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful
10 sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways
15 (hypoalgesia).

Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis.

Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome.

- 20 Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of neurodegenerative and neuroinflammatory diseases. Neurodegenerative and neuroinflammatory diseases include Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt–Jakob disease (CJD) and new variant
25 Creutzfeldt–Jakob disease (nvCJD); Amyotrophic lateral sclerosis, amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease.

- Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or
30 pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of bone and joint diseases. Bone and joint diseases include arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue
35 disorder; spondyloarthropathies; periodontal disease such as periodontitis; arthritides

associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis; Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondyloarthropathy; septic arthritis and other
5 infection-related arthropathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus
10 erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis,
15 Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; Familial Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; and drug-induced arthralgias, tendonitis, and myopathies including dystrophies and other inflammatory myopathies.

20 Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of obstructive diseases of the airways. Obstructive diseases of the airways include asthma, including bronchial, allergic, intrinsic, and extrinsic asthma, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both
25 intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias,
30 fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis
35 including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic

rhinitis including rhinitis nervosa (hay fever); nasal polyposis; and acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus.

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or
5 pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of cardiovascular diseases. Cardiovascular diseases include atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis; inflammatory and auto-immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides;
10 and disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins.

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of eye diseases. Eye diseases include blepharitis; conjunctivitis, including perennial and
15 vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; and infections of the eyes including viral, fungal, and bacterial infections.

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or
20 pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of skin diseases. Skin diseases include psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema,
25 vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; and drug-induced disorders including fixed drug
30 eruptions.

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of abdominal and gastrointestinal tract diseases. Abdominal and gastrointestinal tract diseases include hepatitis, including autoimmune, alcoholic and viral hepatitis; fibrosis and

cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; non-inflammatory diarrhea; glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; Coeliac disease, irritable bowel disease/syndrome, and food-related allergies which may have effects remote from the gut, for example migraine, rhinitis or eczema; allograft rejection including acute and chronic allograft rejection following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; and chronic graft versus host disease;

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of genitourinary diseases. Genitourinary diseases include nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, hemorrhagic cystitis, prostatitis, epididymitis, oophoritis and salpingitis; vulvovaginitis; Peyronie's disease; and erectile dysfunction, both male and female.

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of cancer. The treatment of cancer includes the treatment of brain tumors, prostate, lung, breast, ovarian, bowel and colon, stomach, pancreatic, skin and bone marrow (including leukaemias) and lymphoproliferative systems, such as non-Hodgkin's and Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumor recurrences, and paraneoplastic syndromes.

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of other auto-immune and allergic disorders. Other auto-immune and allergic disorders include Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE syndrome, and antiphospholipid syndrome.

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of other disorders with an inflammatory or immunological component. Other disorders with an inflammatory or immunological component include acquired immune deficiency syndrome (AIDS), leprosy, Sezary syndrome, and paraneoplastic syndromes.

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of mood, depression, sleep and anxiety disorders.

Further, the compounds of formula (I) according to any one of embodiments 1) to 25), or
5 pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of injury induced trauma and spinal cord injury.

Especially, compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and
10 disorders:

1) Pain, wherein pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain
15 associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer
20 chemotherapy; and post operative pain;

Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal
25 surgery, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the
30 stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia);

Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;

Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;

- 5 2) Neurodegenerative and neuro-inflammatory diseases such as Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt–Jakob disease (CJD) and new variant Creutzfeldt–Jakob disease (nvCJD); amyloidosis; Amyotrophic lateral sclerosis, multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease;
- 10 3) Bone and joint diseases such as arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue disorder; spondyloarthropathies; periodontal disease such as periodontitis; Behcet's disease; primary and secondary Sjogren's syndrome;
- 15 systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its
- 20 systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; and drug-induced arthralgias, tendonitis, and myopathies;
- 25 4) Obstructive diseases of the airways such as chronic obstructive pulmonary disease (COPD); cystic fibrosis; lung emphysema; sarcoidosis; farmer's lung and related diseases; lung fibrosis, including fibrosis complicating tuberculosis; and chronic cough associated with inflammatory and secretory conditions of the airways;
- 30 5) Cardiovascular diseases such as inflammatory and auto-immune cardio-myopathies;
- 6) Eye diseases such as degenerative or inflammatory disorders affecting the retina;

- 7) Skin diseases such as psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses; and discoid lupus erythematosus;
- 8) Abdominal and gastrointestinal tract diseases such as fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; Crohn's disease; colitis including ulcerative colitis; and irritable bowel disease/syndrome;
- 9) Genitourinary diseases such as nephritis including interstitial and glomerulonephritis; nephrotic syndrome; and cystitis including acute and chronic (interstitial) cystitis; and
- 10) Other auto-immune and allergic disorders such as Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE syndrome, and antiphospholipid syndrome.

Most preferably, compounds of formula (I) according to any one of embodiments 1) to 25), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and disorders:

- 1) Pain, wherein pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain (preferred); lower back and neck pain; inflammatory pain; neuropathic pain (preferred); visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain;

Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic,

static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia);

5 Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;
Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;

2) Rheumatoid arthritis and osteoarthritis;

10 3) Chronic obstructive pulmonary disease (COPD); and

4) Crohn's disease.

The invention also relates to the use of a compound of formula (I) according to any one of embodiments 1) to 25) for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of the above-mentioned diseases.

15 The present invention also relates to pharmaceutically acceptable salts and to pharmaceutical compositions and formulations of compounds of formula (I) according to any one of embodiments 1) to 25).

A pharmaceutical composition according to the present invention contains at least one compound of formula (I) according to any one of embodiments 1) to 25) (or a
20 pharmaceutically acceptable salt thereof) as the active agent and optionally carriers and/or diluents and/or adjuvants.

The compounds of formula (I) according to any one of embodiments 1) to 25) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such as especially oral) or parenteral
25 administration (including topical application or inhalation).

The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, *The Science and Practice of Pharmacy*, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of
30 formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I) according to any one of embodiments 1) to 25), or a pharmaceutically acceptable salt thereof.

5 Any reference to a compound of formula (I), (I_{ST1}) or (I_{ST2}) in this text is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient. The preferences indicated for the compounds of formula (I) of course apply *mutatis mutandis* to the compounds of formula (I_{ST1}) and the compounds of formula (I_{ST2}) as well as to the salts and pharmaceutically
10 acceptable salts of the compounds of formula (I), of formula (I_{ST1}) and of formula (I_{ST2}). The same applies to these compounds as medicaments, to pharmaceutical compositions containing these compounds as active principles or to the uses of these compounds for the manufacture of a medicament for the treatment of the diseases according to this invention.

15 Unless used regarding temperatures, the term “about” (or alternatively “around”) placed before a numerical value “X” refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X. In the particular case of temperatures, the term “about” (or alternatively “around”) placed before a temperature “Y” refers in the current application
20 to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C. Besides, the term “room temperature” (RT) as used herein refers to a temperature of about 25°C.

Whenever the word “between” is used to describe a numerical range, it is to be understood that the end points of the indicated range are explicitly included in the range.
25 For example: if a temperature range is described to be between 40 °C and 80 °C, this means that the end points 40 °C and 80 °C are included in the range; or if a variable is defined as being an integer between 1 and 4, this means that the variable is the integer 1, 2, 3, or 4.

The compounds of Formula (I) can be manufactured by the methods given below, by the
30 methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.


If not indicated otherwise, the generic groups **R¹**, **R²**, **R³**, **X** and **n** are as defined for formula (I). Other abbreviations used are defined in the experimental section.

In some instances the generic groups R^1 , R^2 , R^3 , X and n might be incompatible with the assembly illustrated in the schemes below and will therefore require the use of protecting groups (PG). The use of protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-Interscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups are as necessary in place.

Preparation of compounds of formula (I):

Compounds of formula (Ia) can be prepared by reaction of an acid (II) with an amine (III) using standard amide coupling reagents such as HOBt/EDC.HCl, TBTU, T_3P or HATU and a base like DIPEA in a solvent like DCM, THF or DMF preferably at temperatures between RT and 45°C (scheme 1).

Compounds of formula (Ib) can be prepared by oxidation of compounds of formula (Ia) with a suitable oxidizing reagent such as 3-chloroperbenzoic acid in a solvent such as DCM or THF at temperatures between 0°C and 45°C.



Scheme 1: Synthesis of compounds of formula (I)

Compounds of formula (II) can be prepared as described in the experimental part below.

Compounds of formula (III), if not commercially available, can be prepared following the procedures outlined in the Schemes below.


Compounds of formula (III), wherein R^2 represents hydrogen and R^3 represents aryl-(C_2 - C_3)alkyl can be prepared from halides (IV), wherein X is preferably bromide or iodide and R^a represents aryl-(C_1 - C_2)alkyl, via a cyanation with NaCN or KCN in a solvent like CH_3CN , EtOH or DMF preferably at temperatures between RT and 65°C. The formed nitriles (V) can be reduced by hydrogenation with Raney Nickel as catalyst in a solvent such as NH_3 in MeOH. Alternatively, a reducing agent such as BH_3 in THF preferably at temperatures between 0°C and 65°C or such as $LiAlH_4$ or $Zn(BH_4)_2$ in a solvent like THF or Et_2O preferably at temperatures between 0°C and 50°C can be used to form amines

(IIIa) (scheme 2). In the same manner, compounds of formula (IIIa), wherein R^a represents aryl, which contain in the aryl part a hydroxy-(C_1 - C_3)alkyl substituent can be prepared from nitriles (V) wherein the aryl part in R^a is substituted with an alkoxy-carbonyl or an alkoxy-carbonyl-(C_1 - C_2)alkyl moiety. In analogy, compounds of formula (III), wherein
5 R^2 represents hydrogen and R^3 represents aryl-methyl (such as benzyl) can be prepared by reduction of nitriles (V) wherein R^a represents aryl (and notably by reduction with BH_3 in THF).

Alternatively, nitriles of formula (V) can be synthesized starting from carboxylic acids of formula (VI), wherein R^a represents aryl-(C_1 - C_2)alkyl or aryl, by preparing the
10 corresponding carboxamides (VII) under standard amide coupling conditions which can be dehydrated using TFAA as dehydrating agent in the presence of Et_3N in a solvent such as DCM preferably at temperatures between $0^\circ C$ and RT.

Alternatively, compounds of formula (III), wherein R^2 represents hydrogen and R^3 represents aryl-(C_1 - C_3)alkyl can be prepared in two steps from aldehydes of formula (VIII),
15 wherein R^a represents aryl-(C_1 - C_2)alkyl or aryl, via formation of the corresponding oximes (IX) using hydroxylamine hydrochloride under standard conditions such as in a solvent like EtOH at temperatures between RT and $60^\circ C$ followed by a reduction of the respective oximes using zinc dust in a solvent like acetic acid preferably at temperatures between $0^\circ C$ and RT or by using BH_3 in a solvent like THF preferably at temperatures between RT
20 and $60^\circ C$.

Compounds of formula (IIIb), wherein R^2 represents methyl, can be synthesized by a reductive amination reaction of a primary amine of formula (IIIa) using formaldehyde via catalytic hydrogenation in the presence of a suitable catalyst such as PtO_2 or Raney Nickel in a solvent like EtOH preferably at temperatures between RT and $45^\circ C$ or in the
25 presence of a reducing agent such as $NaBH_4$ or $NaBH(OAc)_3$ in a solvent like MeOH or $ClCH_2CH_2Cl$ at temperatures between RT and $65^\circ C$. Alternatively, methylation with MeI in the presence of a base such as NaH in a suitable solvent like THF or DMF at temperatures between $0^\circ C$ and RT can be done (scheme 2).



Scheme 2: Synthesis of compounds of formula (III)

wherein R^3 represents aryl-(C_1 - C_3)alkyl

Compounds of formula (X), wherein "aryl" represents an aryl group which is part of R^3 representing aryl-(C_1 - C_3)alkyl and wherein R^b is a (C_1 - C_4)alkyl, (C_3 - C_6)cycloalkyl, (C_1 - C_4)alkoxy, hydroxy-(C_2 - C_3)alkoxy, hydroxymethyl, (C_1 - C_2)alkoxymethyl or hydroxy-(C_2 - C_3)-alkoxymethyl substituent can be prepared following the procedures outlined in scheme 3.

Compounds of formula (X), wherein "aryl" represents an aryl group which is part of R^3 representing aryl-(C_1 - C_3)alkyl and wherein R^b is a (C_1 - C_4)alkyl or a (C_3 - C_6)cycloalkyl substituent can be prepared from compounds of formula (XI) wherein X is a halogen atom (preferably bromide), by a Suzuki type coupling reaction. The Suzuki reaction can be carried out for instance with (C_1 - C_4)alkylboronic acid derivatives or (C_3 - C_6)cycloalkylboronic acid derivatives (e.g. ethylboronic acid) in the presence of a suitable base such as K_3PO_4 and a palladium catalyst like palladium acetate with triphenylphosphine in a solvent such as toluene or dioxane preferably at temperatures between RT and $100^\circ C$.

Compounds of formula (X), wherein "aryl" represents an aryl group which is part of R^3 representing aryl-(C_1 - C_3)alkyl and wherein R^b is a (C_1 - C_4)alkoxy or a hydroxy-(C_2 - C_3)alkoxy substituent, can be prepared from compounds of formula (XII) by an alkylation reaction using a base like K_2CO_3 or Cs_2CO_3 in a solvent such as DMF in the presence of the appropriate alkylating agent such as (C_1 - C_4)alkyl-L or hydroxy-(C_2 - C_3)alkyl-L, wherein L represents a leaving group such as bromide or iodide (e.g., iodomethane).

Compounds of formula (X), wherein "aryl" represents an aryl group which is part of R^3 representing aryl-(C_1 - C_3)alkyl and wherein R^b is a hydroxymethyl, a (C_1 - C_2)alkoxymethyl or a hydroxy-(C_2 - C_3)alkoxymethyl substituent, can be prepared from compounds of formula (XIII) by (1) a Wohl-Ziegler type bromination reaction using standard conditions like NBS in the presence of catalytical amounts of AIBN in a solvent such as


chlorobenzene preferably at temperatures between 40°C and 80°C and (2) followed by a substitution reaction of the respective benzyl bromide with for instance NaOH, NaOMe, NaOEt or AcO-(C₂-C₃)alkyl-ONa.

Compounds of formula (X), wherein "aryl" represents an aryl group which is part of R³ representing aryl-(C₁-C₃)alkyl and wherein R^b is a hydroxyethyl, (C₁-C₂)alkoxyethyl or hydroxy-(C₂-C₃)alkoxyethyl substituent, can be prepared from compounds of formula (XI) by (1) a Stille type coupling reaction using for instance ethyl tributylstannylacetate in the presence of a suitable catalyst such dichlorobis(tri-*o*-tolylphosphine)palladium optionally in combination with zinc bromide in a solvent such as DMF preferably at temperatures between RT and 80°C and (2) followed by a reduction of the corresponding ester with LiAlH₄ in a solvent such as THF preferably at temperatures between 0°C and RT and optionally (3) followed by an alkylation reaction using a base like K₂CO₃ or Cs₂CO₃ in a solvent such as DMF in the presence of the appropriate alkylating agent such as (C₁-C₂)alkyl-L or hydroxy-(C₂-C₃)alkyl-L, wherein L represents a leaving group such as bromide or iodide (e.g., iodomethane).

Compounds of formula (X), wherein "aryl" represents an aryl group which is part of R³ representing aryl-(C₁-C₃)alkyl and wherein R^b is a hydroxypropyl, (C₁-C₂)alkoxypropyl or hydroxy-(C₂-C₃)alkoxypropyl substituent, can be prepared from compounds of formula (XI) by (1) a Heck type coupling using for instance methylacrylate in the presence of a base such as Et₃N and a suitable palladium catalyst like tetrakis(triphenylphosphine)palladium in a solvent such as DMF preferably at temperatures between RT and 100°C and (2) followed by a reduction of the corresponding unsaturated ester with LiAlH₄ in a solvent such as THF preferably at temperatures between 0°C and RT and optionally (3) followed by an alkylation reaction using a base like K₂CO₃ or Cs₂CO₃ in a solvent such as DMF in the presence of the appropriate alkylating agent such as (C₁-C₂)alkyl-L or hydroxy-(C₂-C₃)alkyl-L, wherein L represents a leaving group such as bromide or iodide (e.g., iodomethane).


The starting materials (XI), (XII) or (XIII) for the transformations described in scheme 3 may be nitriles of formula (V), aldehydes of formula (VIII) or amines of formula (IIIa), wherein the amino-function is protected by a protecting group such as a phthalimide group, which group may be cleaved after the respective transformation as described in scheme 3 with, for instance, hydrazine in a solvent like EtOH at a temperature around RT. Preferred starting materials for the transformation of compounds of formula (XI) to compounds of formula (X) are amines of formula (IIIa), wherein the amino-function is protected by a protecting group such as a phthalimide group and wherein R^a represents

aryl or aryl-(C₁-C₂)alkyl. Preferred starting materials for the transformation of compounds of formula (XII) to compounds of formula (X) are aldehydes of formula (VIII), wherein R^a represents aryl. Preferred starting materials for the transformation of compounds of formula (XIII) to compounds of formula (X) are nitriles of formula (V), wherein R^a represents aryl.



Scheme 3: Synthesis of compounds of formula (X)


Compounds of formula (III), wherein R² represents hydrogen and R³ represents an aryl-(C₁-C₃)alkyl group or a (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl group which groups are in the alkyl part mono-substituted with hydroxy can be prepared from amino acid derivatives (XIV), wherein R^c is aryl, aryl-methyl or (C₃-C₇)cycloalkyl and R represents (C₁-C₄)alkyl (preferably methyl or ethyl), via reduction with LiAlH₄ or BH₃ in a solvent such as THF or by using NaBH₄ in MeOH preferably at temperatures between 0°C and RT to form the respective aminoalcohols (scheme 4). Compounds of formula (IIId), wherein R² represents methyl, can be synthesized under the conditions mentioned above.



Scheme 4: Synthesis of compounds of formula (III) wherein R³ represents an aryl-(C₁-C₃)alkyl group or a (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl group which groups are in the alkyl part mono-substituted with hydroxy


Compounds of formula (III), wherein R² represents hydrogen and R³ represents (C₅-C₇)cycloalkyl, which is annelated with an optionally substituted phenyl can be prepared in two steps from ketones (XV), wherein R represents halogen and m represents 0, 1, 2 or 3 via (1) oxime formation using standard conditions such as O-methylhydroxylamine in a solvent like MeOH optionally in the presence of NaOAc to form compounds of formula

(XVI) and (2) a hydrogenation reaction in the presence of a reducing agent such as BH_3 in a solvent like THF preferably at temperatures between RT and 60°C (scheme 5). Compounds of formula (III_f), wherein R^2 represents methyl, can be prepared under the conditions mentioned above.



Scheme 5: Synthesis of compounds of formula (III) wherein R^3 represents $(\text{C}_5\text{-C}_7)$ cycloalkyl, which is annelated with an optionally substituted phenyl

Alternatively, compounds of formula (III), wherein R^2 represents hydrogen and R^3 represents aryl-methyl, can be prepared from aniline derivatives (XVII) by a Meerwein arylation type reaction using a Cu(II) salt like CuCl_2 , tBu-nitrite and 1,1-dichloroethylene in a solvent like CH_3CN followed by refluxing in MeOH in the presence of sodium methoxide and subsequent treatment with concentrated H_2SO_4 , preferably at a temperature between RT and 90°C . Hydrolysis of the obtained ester derivatives using standard conditions such as NaOH or LiOH in a mixture of water and a suitable organic solvent such as MeOH, EtOH or THF gives the corresponding compounds of formula (XVIII). A Curtius rearrangement using DPPA in a suitable solvent like toluene preferably at temperatures around 100°C followed by treatment with water or potassium trimethylsilanolate at temperatures around 0°C leads to compounds of formula (III_g), wherein R^2 is hydrogen (scheme 6). Compounds of formula (III_h), wherein R^2 represents methyl and R^3 represents aryl-methyl, can be prepared under the methylation conditions mentioned above.




Scheme 6: Synthesis of compounds of formula (III) wherein R^3 represents aryl-methyl

Compounds of formula (III), wherein R^2 represents hydrogen and R^3 represents an aryl- $(\text{C}_1\text{-C}_3)$ alkyl group or a heteroaryl- $(\text{C}_1\text{-C}_3)$ alkyl group which groups are in the alkyl part

mono-substituted with heterocyclyl, can be prepared in analogy to the methods described in WO2009/132000 or following the procedures outlined in scheme 7 below.


Compounds of formula (XX), wherein Y represents O or CF₂, can be prepared from aldehydes (XIX), wherein R^d represents aryl or heteroaryl, by a Strecker condensation with the respective heterocyclyl group in the presence of TMSCN in a solvent such as DCM or CH₃CN, preferably at temperatures between 0°C and RT. Hydrogenation of aminonitriles (XX) in the presence of a catalyst like Raney Nickel in a solvent such as NH₃ in MeOH gives the respective amines (IIIi), wherein Y represents O or CF₂. Compounds of formula (IIIj), wherein R² represents methyl, can be prepared under the conditions mentioned above.



Scheme 7: Synthesis of compounds of formula (III), wherein R³ represents an aryl-(C₁-C₃)alkyl group or a heteroaryl-(C₁-C₃)alkyl group which groups are in the alkyl part mono-substituted with heterocyclyl

Compounds of formula (III), wherein R² represents hydrogen and R³ represents a (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl group which is in the cycloalkyl part mono-substituted with aryl or heteroaryl can be prepared in analogy to the methods described in WO2009/012482 or following the procedure outlined in Scheme 8 below.


The starting acetonitrile derivatives (XXI), wherein R^e represents aryl or heteroaryl can be alkylated with dihaloalkanes such as 1-bromo-2-chloroethane, 1,3-dibromopropane, 1,4-dibromobutane or 1,5-dibromopentane in the presence of a base like NaH or tBuOK in a suitable organic solvent such as THF or DMSO preferably at temperatures between 0°C and RT to form the respective compounds of formula (XXII). Reduction of nitriles (XXII) can be carried out by hydrogenation with Raney Nickel as catalyst in a solvent such as NH₃ in MeOH. Alternatively, a reducing agent such as BH₃ in THF can be used preferably at temperatures between RT and 65°C (scheme 8). Compounds of formula (IIIIm) wherein R² represents methyl can be prepared under the conditions mentioned above.



Scheme 8: Synthesis of compounds of formula (III) wherein R^3 represents a ($\text{C}_3\text{-C}_7$)cycloalkyl-methyl group which is in the cycloalkyl part mono-substituted with aryl or heteroaryl

Compounds of formula (III), wherein R^2 represents hydrogen and R^3 represents a ($\text{C}_3\text{-C}_7$)cycloalkyl-methyl group which is in the cycloalkyl part mono-substituted with hydroxy can be prepared via a cyanation of ketones (XXIII) using NaCN or TMS-CN in a suitable solvent like acetic acid preferably at temperatures between 0°C and RT (scheme 9).


Reduction of cyanohydrines (XXIV) can be carried out as described above for compounds of formula (XXII). Compounds of formula (IIIo), wherein R^2 represents methyl, can be prepared under the conditions mentioned above.



Scheme 9: Synthesis of compounds of formula (III) wherein R^3 represents a ($\text{C}_3\text{-C}_7$)cycloalkyl-methyl group which is in the cycloalkyl part mono-substituted with hydroxy

Compounds of formula (III), wherein R^2 represents hydrogen and R^3 represents a cyclohexyl-alkyl group which is in the cyclohexyl part di-substituted with fluoro can be prepared as described in scheme 10. For instance, a tandem double Michael addition-Dieckmann condensation reaction with methylacrylate [J.Org.Chem., 72, 7455-7458 (2007)] of the respective acetonitrile derivative (XXV) followed by a Krapcho decarboxylation under standard conditions using wet DMSO as solvent in the presence of a halide anion (e.g., LiCl) preferably at temperatures between 100°C and 150°C and difluorination using DAST in a solvent such as DCM preferably at temperatures between -78°C and RT gives the respective difluorine compounds of formula (XXVIII) (scheme 10).

Reduction of nitriles (XXVIII) can be carried out as described above for compounds of formula (XXII). Compounds of formula (IIIq), wherein R^2 represents methyl, can be prepared under the conditions mentioned above.



Scheme 10: Synthesis of compounds of formula (III) wherein R³ represents a cyclohexyl-alkyl group which is in the cyclohexyl part di-substituted with fluoro

5 Experimental Part

Abbreviations (as used herein and in the description above)

	Ac	acetyl
	AIBN	azobisisobutyronitrile
	anh.	anhydrous
10	aq	aqueous
	ATP	adenosine-5'-triphosphate
	CC	column chromatography
	cDNA	complementary desoxyribonucleic acid
	CNS	central nervous system
15	DAST	diethylaminosulfur trifluoride
	DCM	dichloromethane
	DEA	diethylamine
	DIPEA	diisopropylethylamine
	DMAP	dimethylaminopyridine
20	DMEM	Dulbecco's modified eagle's medium
	DMF	dimethylformamide
	DMSO	dimethylsulfoxide

	DNA	desoxyribonucleic acid
	DPPA	diphenylphosphoryl azide
	Et	ethyl
	EDC.HCl	N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
5	FCS	fetal calf serum
	FLIPR	fluorescent imaging plate reader
	h	hour(s)
	HATU	2-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
	Hept	heptanes
10	HMDA	hexamethyldisilazide
	HOAT	1-hydroxy-7-azabenzotriazole
	HOBT	1-hydroxybenzotriazole hydrate
	HV	high vacuum
	ID	inner diameter
15	LC-MS	liquid chromatography – mass spectrometry
	LDA	lithium diisopropylamide
	M	molar
	Me	methyl
	min	minute(s)
20	MTBE	methyl tert.-butyl ether
	N	normal
	NBS	N-bromosuccinimide
	NFSI	N-fluorobenzenesulfonimide
	NMR	nuclear magnetic resonance
25	PBS	phosphate buffered saline
	PG	protecting group
	R _f	retention factor
	RNA	ribonucleic acid
	RT	room temperature
30	sat.	saturated
	TBTU	O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
	tBu	tert.-butyl
	TFA	trifluoroacetic acid
	TFFA	trifluoroacetic anhydride
35	THF	tetrahydrofuran

	TLC	thin layer chromatography
	TMS	trimethylsilyl
	T ₃ P	propylphosphonic anhydride
	t _R	retention time
5	UV	ultra-violet
	Vis	visible

Characterization methods used

NMR: Bruker Avance 400, 400 MHz ; chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet, br = broad, coupling constants are given in Hz.

LC-MS: Thermo Finnigan MSQ Surveyor MS with Agilent 1100 Binary Pump and DAD. Conditions: eluents: A: H₂O + 0.04% TFA; B: CH₃CN; gradient: 5% B → 95% B; runtime: 1.5 min ; flow: 4.5 mL/min; detection: UV/Vis + MS, t_R is given in min.

LC-MS (A): column Waters XBridge C18, 2.5 μm, 4.6x30 mm

15 LC-MS (B): column Waters Atlantis T3, 5 μm, 4.6x30 mm

LC-MS (C): column Zorbax SB-aq, 3.5 μm, 4.6x50 mm

Conditions: LC-MS (D): eluents: A: H₂O + 13 mmol/L NH₄OH; B: CH₃CN ; gradient: 5% B → 95% B ; runtime: 1.5 min ; flow: 4.5 mL/min; detection: UV/Vis + MS, t_R is given in min; column Waters XBridge C18, 2.5 μm, 4.6x50 mm. LC-MS: Waters Acquity UPLC (ACQ-CM, -ACQ-BSM-ACD-SM)

Conditions: LC-MS (E): eluents: A: H₂O + 0.05% v/v formic acid; B: CH₃CN + 0.045% v/v formic acid; gradient: 2% B → 98% B; runtime: 2 min; flow: 1.2 mL/min; detection: UV 214 nm + ELSD and MS; column Acquity UPLC CSH C18 1.7 μm, 2.1x50 mm.

Conditions: LC-MS (F): eluents: A: H₂O + 0.05% v/v TFA; B: CH₃CN + 0.045% v/v TFA; gradient: 2% B → 98% B; runtime: 2 min; flow: 1.2 mL/min; detection: UV 214 nm + ELSD and MS; column Acquity UPLC CSH C18 1.7 μm, 2.1x50 mm.

TLC: *silica gel 60 F₂₅₄ Merck*, 0.25 mm layer thickness

Purification methods used

Column chromatography (CC) (G) was performed using *silica gel 60 Merck* (0.063-0.200 mm) or using prepacked cartridges (SNAP KP-SILTM, SNAP KP-NHTM, IsoluteTM) from Biotage.

Preparative LC-MS (normal phase): flow: 40 mL/min. Detection: UV-Vis and/or MS.

Column: Macherey-Nagel Nucleosil SiOH, 10 μ M, 21x100 mm

Eluents: A = Hept, B = EtOAc, C = MeOH

Conditions (H):

t (min)	0	0.4	0.5	6.0	6.2	7.8	7.9	8.8	8.9	9.0
% A	90	90	70	40	25	25	0	0	90	90
% B	10	10	30	55	70	70	30	30	10	10
% C	0	0	0	5	5	5	70	70	0	0

5 Conditions (I):

t (min)	0	0.4	0.5	6.0	6.2	7.8	7.9	8.8	8.9	9.0
% A	90	90	50	20	10	10	0	0	90	90
% B	10	10	50	65	70	70	30	30	10	10
% C	0	0	0	15	20	20	70	70	0	0

Preparative LC-MS (reverse phase): flow: 75 mL/min. Detection: UV-Vis and/or MS.

XBridge: column Waters XBridge C18, 10 μ m, 30x75 mm

Acidic: eluent: A = H₂O with 0.5% formic acid, B = CH₃CN

10 Basic: eluent: A = H₂O with 0.125% NH₄OH, B = CH₃CN

Apolar gradient: 30% B → 95% B over 3.5 min then 95% B over 2.5 min

Normal gradient: 20% B → 95% B over 4 min then 95% B over 2 min

Polar gradient: 10% B → 95% B over 4 min then 95% B over 2 min

Very polar gradient: 5% B → 50% B over 3 min then 50% B → 95% B over 1 min and finally 95%B over 2 min

15

Extremely polar gradient: 0% B over 1 min then 0% B → 20% B over 2.5 min then 20% B → 95% B over 0.5 min and finally 95%B over 2 min

	acidic	basic
apolar gradient	(J)	(K)
normal gradient	(L)	(M)
polar gradient	(N)	(P)
very polar gradient	(Q)	(T)
extremely polar gradient	(U)	(V)

Racemates can be separated into their enantiomers by preparative chiral HPLC. The respective conditions are described below.

The following examples illustrate the invention but do not at all limit the scope thereof.

A. Preparation of precursors and intermediates:

5 A.1 Synthesis of carboxylic acid derivatives (II)

A.1.1 Synthesis of 3-fluoro-2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid

A.1.1.1 Synthesis of furo[2,3-*b*]pyridine-3-carboxylic acid

To a suspension of furo[2,3-*b*]pyridine-3-carboxaldehyde (67 mmol) [J.Heterocyclic Chem., 23, 1465 (1986)] in 52 mL H₂O were added NaH₂PO₄ (67 mmol), 260 mL t-BuOH,
10 71 mL 2-methyl-2-butene followed by portionwise addition of NaClO₂ (100 mmol) at 0°C. After 15 min, the cooling bath was removed and the reaction was stirred at RT for 24 h. A solution of sat. aq. NaHCO₃ was added and the mixture was extracted with EtOAc. The water phase was acidified with 1N HCl solution and it was then extracted 3 times with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo
15 to obtain the desired compound as beige solid.

LC-MS (A): t_R = 0.41 min; [M+H]⁺: 164.21.

A.1.1.2 Synthesis of furo[2,3-*b*]pyridine-3-carboxylic acid methyl ester

To a suspension of furo[2,3-*b*]pyridine-3-carboxylic acid (53 mmol) in 85 mL DCM were added EDC.HCl (58 mmol), DMAP (16 mmol) and 4.3 mL MeOH. The beige suspension
20 was stirred at RT for 2 h. The reaction mixture was diluted with 50 mL DCM and quenched with sat. aq. NaHCO₃ solution. The organic phase was washed 3 times with sat. aq. NH₄Cl solution and once with brine. The organic layer was dried over MgSO₄ and concentrated in vacuo to obtain the desired compound as grey solid.

LC-MS (A): t_R = 0.56 min; [M+H]⁺: 178.14.

25 A.1.1.3 Synthesis of 2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid methyl ester

To a suspension of furo[2,3-*b*]pyridine-3-carboxylic acid methyl ester (48 mmol) in 180 mL MeOH was added NaOAc (97 mmol). The flask was evacuated and filled three times with argon, 20% wet Pd(OH)₂ on carbon (1000 mg) was added and the reaction was stirred for
30 20 h under a hydrogen atmosphere. It was then filtered over a 2 cm pad of celite and was washed with EtOH (50 mL) and EtOAc (50 mL). The filtrate was concentrated in vacuo to afford the desired compound as colorless oil.

LC-MS (A): t_R = 0.40 min; [M+H]⁺: 180.26.

A.1.1.4 Synthesis of 3-fluoro-2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid methyl ester

To a solution of LiHMDA (1.4 mmol, 1M in THF) in 1 mL THF was added a solution of 2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid methyl ester (0.56 mmol) in 1 mL THF at -78°C. After 45 min, NFSI (0.83 mmol), dissolved in 1mL THF, was dropwise added still at -78°C. The reaction mixture was stirred overnight allowing to warm slowly to RT. The reaction was quenched with sat. aq. NaHCO₃ solution and extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried over MgSO₄ and concentrated in vacuo. Purification by CC using Hept/EtOAc (7/3 to 3/7) gives the desired product as white solid.

LC-MS (A): t_R = 0.48 min; [M+H]⁺: 198.20.

A.1.1.5 Synthesis of 3-fluoro-2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid

To a solution of 3-fluoro-2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid methyl ester (0.30 mmol) in 3 mL EtOH and 2 mL MeOH was added a solution of LiOH.H₂O (0.33 mmol) in 1 mL H₂O. The reaction was stirred at RT for 50 min. The reaction mixture was diluted with 10 mL EtOAc and extracted twice with water. The water phase was acidified to pH 3 and extracted 3 times with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo to obtain the desired product as white solid.

LC-MS (A): t_R = 0.20 min; [M+H]⁺: 184.08.

A.1.2 Synthesis of 2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid

To a solution of 2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid methyl ester (21.2 mmol) in 20 mL EtOH and 15 mL MeOH was added a solution of LiOH.H₂O (23.3 mmol) in 6 mL H₂O. After stirring at RT for 1 h, the reaction mixture was diluted with 20 mL EtOAc and extracted twice with water. The water phase was acidified to pH 3 and extracted 5 times with EtOAc and 3 times with DCM. The combined organic layers were dried over MgSO₄ and concentrated in vacuo to obtain the desired product as beige solid.

LC-MS (A): t_R = 0.25 min; [M+H]⁺: 166.00.

A.1.3 Synthesis of 3,4-dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid**A.1.3.1 Synthesis of 3-(2-chloropyridin-3-yl)-3-hydroxypropanoic acid ethyl ester**

To a solution of 14.5 mL diisopropylamine in 336 mL THF was added 49 mL n-BuLi (2.5 M in hexanes) at 0°C. The mixture was stirred at 0°C for 15 min, cooled to -78°C before 10 mL EtOAc were dropwise added. After another 30 min, a solution of 2-chloro-3-pyridine carboxaldehyde (84.8 mmol), dissolved in 84 mL THF, was added. The mixture was

stirred at -78°C for 30 min and then allowed to warm to RT. After stirring for 1.5 h, the reaction was quenched with sat. aq. NaHCO₃ solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO₄ and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept/EtOAc (10/1) to EtOAc gives the desired compound as yellow oil.

LC-MS (A): t_R = 0.51 min; [M+H]⁺: 230.19.

A.1.3.2 Synthesis of 1-(2-chloropyridin-3-yl)propane-1,3-diol

To a solution of 3-(2-chloropyridin-3-yl)-3-hydroxypropanoic acid ethyl ester (66.7 mmol) in 47 mL THF was added a suspension of LiAlH₄ (100 mmol) in 219 mL THF at 0°C. The mixture was stirred at 0°C for 1 h and was then quenched by adding consecutively 3.8 mL water, 3.8 mL 15% aq. NaOH solution and 11.4 mL water. The mixture was filtrated and the residue was washed with MTBE and EtOAc. The filtrate was dried over MgSO₄ and concentrated in vacuo to obtain the desired product as yellow solid.

LC-MS (A): t_R = 0.29 min; [M+H]⁺: 188.19.

A.1.3.3 Synthesis of 3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ol

A mixture of 1-(2-chloropyridin-3-yl)propane-1,3-diol (62.9 mmol) and KOtBu (189 mmol) in 240 mL tBuOH (dried over 3Å molsieves) was heated to 80°C for 2.5 h. The reaction mixture was then concentrated to about ¼ of its volume, diluted with water and extracted 5 times with DCM. The combined organic layers were washed with brine, dried over MgSO₄ and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using MeOH/DCM (99/1 to 95/5) gives the desired compound as orange oil.

LC-MS (A): t_R = 0.13 min; [M+H]⁺: 152.21.

A.1.3.4 Synthesis of 4-chloro-3,4-dihydro-2H-pyrano[2,3-b]pyridine

To a mixture of 3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ol (21 mmol) in 80 mL DCM was added 2.3 mL thionyl chloride at 0°C. The reaction mixture was stirred at 0°C for 10 min and then at reflux for 30 min. After cooling to RT, sat. aq. NaHCO₃ solution was added and the mixture was extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried over MgSO₄ and concentrated in vacuo to obtain the desired product as orange oil.

LC-MS (A): t_R = 0.41 min; [M+H]⁺: 170.01.

A.1.3.5 Synthesis of 3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carbonitrile

To a mixture of 4-chloro-3,4-dihydro-2H-pyrano[2,3-b]pyridine (18.7 mmol) in 60 mL DMF was added KCN (56.1 mmol) and the mixture was stirred at 90°C overnight. After cooling

to RT, the mixture was diluted with aq. 0.5 M NaOH solution and extracted 3 times with EtOAc. The combined organic layers were washed again with aq. 0.5 M NaOH solution and once with brine. The organic phase was dried over MgSO_4 and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept/EtOAc (4/1) to EtOAc gives the desired compound as yellow oil.

LC-MS (A): t_R = 0.28 min; $[\text{M}+\text{H}]^+$: 161.10.

A.1.3.6 Synthesis of 3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carboxylic acid

A solution of 3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carbonitrile (8.87 mmol) in 17.6 mL aq. 32% HCl solution was stirred at 90°C for 3 h. The reaction mixture was then concentrated, the remaining solid was suspended in MeOH and filtrated. Evaporation of the solvent gives the desired product as yellow solid.

LC-MS (A): t_R = 0.15 min; $[\text{M}+\text{H}]^+$: 180.27.

A.1.4 Synthesis of 4-fluoro-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carboxylic acid

A.1.4.1 Synthesis of 4-fluoro-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carbonitrile

To a solution of 3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carbonitrile (0.62 mmol) in 4.5 mL THF was added NaHMDA (0.75 mmol, 1 M in THF) at -78°C. After 1 h, a solution of NFSI (0.75 mmol) in 0.5 mL THF was added at -78°C. The mixture was stirred at -78°C for 30 min, at 0°C for 2 h and finally at RT overnight. The reaction was quenched with sat. aq. NaHCO_3 solution and extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept to Hept/EtOAc (4/1) gives the desired compound as colorless solid.

LC-MS (A): t_R = 0.50 min; $[\text{M}+\text{H}]^+$: 179.23.

A.1.4.2 Synthesis of 4-fluoro-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carboxylic acid

A solution of 4-fluoro-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carbonitrile (0.09 mmol) in 0.2 mL aq. 32% HCl solution was stirred at 90°C for 3 h. The reaction mixture was then concentrated and dried at HV to give the desired product as yellow oil.

LC-MS (A): t_R = 0.15 min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 239.23.

A.2 Synthesis of amino derivatives (III)

A.2.1 Synthesis of 2-amino-2-cycloheptylethanol

A.2.1.1 Synthesis of 2-amino-2-cycloheptylacetic acid tert-butyl ester

To a solution of N-(diphenylmethylene)glycerine tert-butyl ester (6.83 mmol) and (*R*)-4,4-dibutyl-2,6-bis(3,4,5-trifluorophenyl)-4,5-dihydro-3*H*-dinaphthol[7,6,1,2-cde]azepinium bromide (6.84 μ mol) in 45 mL toluene were sequentially added cycloheptyl bromide (8.2 mmol) and CsOH H₂O (34.2 mmol) at -10°C. The reaction mixture was stirred at -10°C for 10 min and then at RT for 4 days. Another portion of (*R*)-4,4-dibutyl-2,6-bis(3,4,5-trifluorophenyl)-4,5-dihydro-3*H*-dinaphthol[7,6,1,2-cde]azepinium bromide (6.84 μ mol) was added and stirring was continued at RT for another 24 h. The reaction was quenched with water and extracted 3 times with DCM. The combined organic layers were combined, concentrated and the residue was redissolved in 100 mL THF. A solution of 100 mL aq. 0.5M citric acid solution was added and the mixture was stirred at RT for 4 h. The mixture was concentrated to half of its volume and extracted twice with Et₂O. The aqueous layer was basified with solid NaHCO₃ and extracted 3 times with DCM. The combined organic layers were dried over MgSO₄ and concentrated in vacuo to obtain the desired product as yellow oil.

LC-MS (A): t_R = 0.61 min; [M+H]⁺: 228.29.

A.2.1.2 Synthesis of 2-amino-2-cycloheptylethanol

To a solution of 3.43 mL LiAlH₄ (1M in THF) in 8 mL THF was added a solution of 2-amino-2-cycloheptylacetic acid tert-butyl ester (1.72 mmol) in 3 mL THF at 0°C. The ice bath was removed and stirring was continued at RT for 1 h. The reaction mixture was cooled to 0°C, quenched with water and a 1M NaOH solution, filtered over a pad of celite and washed with EtOAc. The filtrate was basified with a 1M NaOH solution to pH 8-9 and it was then extracted 3 times with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo to obtain the crude product as yellow oil. The crude was dissolved in 3 mL Et₂O and a solution of 4M HCl in dioxane was dropwise added at 0°C. The resulting precipitate was separated by filtration and dried in vacuo to give the corresponding HCl salt as yellow solid.

LC-MS (A): t_R = 0.39 min; [M+H]⁺: 158.14.

A.2.2 Synthesis of 2,4-dichloro-6-fluorobenzylamine

A.2.2.1 Synthesis of 2,4-dichloro-6-fluorobenzonitrile

To a solution of 2,4-dichloro-6-fluorobenzamide (5.07 mmol) (US 20060178386) in 74 mL DCM were added Et₃N (15.2 mmol) followed by TFAA (10.1 mmol) at 0°C. After 30min, water was added, the organic layer was separated and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept/EtOAc (4/1 to 1/3) gives the desired compound as colorless solid.

LC-MS (A): t_R = 0.80 min; ^1H NMR ($(\text{CD}_3)_2\text{SO}$) δ : 7.94 (s, 1H), 7.91 (s, 1H).

A.2.2.2 Synthesis of 2,4-dichloro-6-fluorobenzylamine

To a solution of 2,4-dichloro-6-fluorobenzonitrile (3.87 mmol) in 15 mL THF was added a solution of BH_3 (15.5 mmol, 1M in THF) and the mixture was stirred at 60°C for 1 h. After cooling to 0°C, water was added followed by MeOH and the mixture was then heated to 70°C for 10 min. The solvent was evaporated, the residue was taken up in water and EtOAc. The aqueous phase was separated, basified with 1M NaOH and it was extracted 3 times with EtOAc. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to obtain the desired product as yellow oil.

LC-MS (A): t_R = 0.39 min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 234.90.

A.2.3 Synthesis of 2,4-dichloro-6-cyclopropylbenzylamine

A.2.3.1 Synthesis of 2-(2-bromo-4,6-dichlorobenzyl)isoindoline-1,3-dione

To a solution of 1-bromo-2-(bromomethyl)-3,5-dichlorobenzene (1.98 mmol) [J.Med.Chem., 35 (22), 4221 (1992)] in 10 mL CH_3CN were added phthalimide (1.98 mmol) and K_2CO_3 (5.93 mmol). The reaction mixture was stirred at 50°C for 6 h and then at RT overnight. Sat. aq. NaHCO_3 solution was added and the mixture was extracted 3 times with DCM. The combined organic phases were dried over MgSO_4 and concentrated in vacuo to obtain the desired product as beige solid.

LC-MS (A): t_R = 0.99 min; ^1H NMR (CDCl_3) δ : 7.91-7.71 (m, 4H), 7.57 (s, 1H), 7.41 (s, 1H), 5.13 (s, 2H).

A.2.3.2 Synthesis of 2,4-dichloro-6-cyclopropylbenzylamine

To a solution of 2-(2-bromo-4,6-dichlorobenzyl)isoindoline-1,3-dione (1.96 mmol) in 16 mL toluene and 0.8 mL water were added K_3PO_4 (6.85 mmol), triphenylphosphine (0.23 mmol), cyclopropylboronic acid (2.35 mmol) and $\text{Pd}(\text{OAc})_2$ (0.15 mmol). The mixture was stirred at 80°C for 24 h when another portion of cyclopropylboronic acid (1.96 mmol) and $\text{Pd}(\text{OAc})_2$ (0.15 mmol) were added. The reaction mixture was stirred at 80°C for further 4 days, cooled to RT, quenched with sat. aq. NaHCO_3 solution and extracted with EtOAc. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give a crude white solid. This solid was dissolved in 15 mL EtOH and 12.6 mL of hydrazine monohydrate was added. After stirring at RT for 30 min, EtOAc was added. The aqueous phase was basified with 1M NaOH solution and extracted 3 times with EtOAc. The combined organic layers were dried over MgSO_4 and concentrated. Purification with CC (KP-NHTM from Biotage) gives the desired compound as red/brown oil.

LC-MS (A): t_R = 0.60 min; $[M+H]^+$: 216.15.

A.2.4 Synthesis of 2,4-dichloro-6-ethylbenzylamine and 2,4-dichloro-6-vinylbenzylamine

To a solution of 2-(2-bromo-4,6-dichlorobenzyl)isoindoline-1,3-dione (4.31 mmol) in 35 mL toluene and 1.7 mL water were added K_3PO_4 (15.1 mmol), triphenylphosphine (0.50 mmol), ethylboronic acid (4.31 mmol) and $Pd(OAc)_2$ (0.32 mmol). The mixture was stirred at 80°C for 48 h when another portion of ethylboronic acid (2.1 mmol) and $Pd(OAc)_2$ (0.32 mmol) were added. The reaction mixture was stirred at 80°C for further 3 days, cooled to RT, quenched with sat. aq. $NaHCO_3$ solution and extracted with EtOAc. The combined organic layers were dried over $MgSO_4$ and concentrated in vacuo to give a white solid. This solid was dissolved in 20 mL EtOH, 10.3 mL of hydrazine monohydrate was added and the mixture was stirred at RT for 35 min. EtOAc was added, the aqueous phase was basified with 1M NaOH solution and extracted 3 times with EtOAc. The combined organic layers were dried over $MgSO_4$ and concentrated to give a mixture of both products as orange oil.

LC-MS (A): t_R = 0.51 min; $[M+H]^+$: 204.05. (2,4-dichloro-6-ethylbenzylamine)

LC-MS (A): t_R = 0.49 min; $[M+H]^+$: 202.04. (2,4-dichloro-6-vinylbenzylamine)

A.2.5 Synthesis of (2-(aminomethyl)-3,5-dichlorophenyl)methanol

A.2.5.1 Synthesis of 2-(bromomethyl)-4,6-dichlorobenzonitrile

A solution of 2,4-dichloro-6-methylbenzonitrile (16.9 mmol) in 34 mL chlorobenzene was heated to 50°C when NBS (18.6 mmol) was added. The flask was purged with Ar before AIBN (1.69 mmol) was added at once still at 50°C. The reaction mixture was then stirred at 78°C. After 2 h and 4 h, another portion of AIBN (1.69 mmol) was added and heating to 78°C was continued overnight. The solvent was then evaporated off, the resulting residue was redissolved in Et_2O and the remaining solid was removed by filtration. The filtrate was washed twice with 2N HCl solution and brine, it was dried over $MgSO_4$ and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept to EtOAc gives the desired compound as yellowish solid.

LC-MS (A): t_R = 0.88 min; 1H NMR ($(CD_3)_2SO$) δ : 8.02 (2, 1H), 7.92 (s, 1H), 4.79 (s, 2H).

A.2.5.2 Synthesis of 3,5-dichloro-2-cyanobenzyl acetate

To a solution of 2-(bromomethyl)-4,6-dichlorobenzonitrile (15.1 mmol) in 30 mL AcOH was added NaOAc (75.7 mmol). The suspension was heated to 100°C for 2 h. The solvent was evaporated off and the residue partitioned between DCM and water. The organic

phase was washed with water, dried over MgSO_4 and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept/EtOAc (95/5 to 30/70) gives the desired compound as white solid.

LC-MS (B): t_R = 0.88 min; ^1H NMR ($(\text{CD}_3)_2\text{SO}$) δ : 8.02 (s, 1H), 7.76 (s, 1H), 5.23 (s, 2H), 2.12 (s, 3H).

A.2.5.3 Synthesis of (2-(aminomethyl)-3,5-dichlorophenyl)methanol

To a solution of 3,5-dichloro-2-cyanobenzyl acetate (11.7 mmol) in 50 mL THF was added a solution of BH_3 (50 mmol, 1M in THF). The reaction mixture was heated to 75°C for 7 h and then cooled to 0°C. Water was added followed by MeOH and the mixture was concentrated. The residue was taken up in water and EtOAc, acidified with 1N HCl solution and extracted with DCM. The aqueous phase was then basified with 1M NaOH solution and extracted with DCM. The combined organic layers were dried over MgSO_4 and concentrated in vacuo. Purification with CC using DCM/ Et_3N (99/1) to DCM/MeOH/ Et_3N (90/10/1) gives the desired compound as pinkish solid.

LC-MS (B): t_R = 0.42 min; ^1H NMR ($(\text{CD}_3)_2\text{SO}$) δ : 7.46 (s, 1H), 7.38 (s, 1H), 4.60 (s, 2H), 3.76 (s, 2H).

A.2.6 Synthesis of 2,4-dichloro-6-methoxybenzylamine

A.2.6.1 Synthesis of 2,4-dichloro-6-methoxybenzaldehyde

To a solution of 4,6-dichlorosalicylaldehyde (2.69 mmol) in 5 mL DMF was added K_2CO_3 (5.39 mmol) followed by iodomethane (2.96 mmol). The reaction mixture was heated to 50°C for 3.5 h. At RT, the mixture was diluted with EtOAc and washed 3 times with water and then with brine. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired product as beige solid.

LC-MS (A): t_R = 0.78 min; ^1H NMR ($(\text{CD}_3)_2\text{SO}$) δ : 10.30 (s, 1H), 7.36 (s, 1H), 7.32 (s, 1H), 3.39 (s, 3H).

A.2.6.2 Synthesis of 2,4-dichloro-6-methoxybenzaldehyde oxime

A solution of 2,4-dichloro-6-methoxybenzaldehyde (2.39 mmol) in 5 mL DMF was cooled to 0°C and NaOAc (2.63 mmol) followed by hydroxylamine HCl (2.63 mmol) were added. The ice bath was removed and the reaction mixture was stirred at RT for 10 min. The mixture was diluted with EtOAc and washed once with water and brine. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired compound as white solid.

LC-MS (A): t_R = 0.73 min; $[\text{M}+\text{H}]^+$: 220.14.

A.2.6.3 Synthesis of 2,4-dichloro-6-methoxybenzylamine

A suspension of 2,4-dichloro-6-methoxybenzaldehyde oxime (2.24 mmol) in 3 mL AcOH was cooled to 0°C and zinc dust (8.53 mmol) was added. The reaction mixture was stirred at RT for 2 h. It was filtered over a pad of celite and washed with EtOAc and MeOH. The
5 filtrate was concentrated and redissolved in water (pH 4 with 2N HCl solution). It was washed once with EtOAc, the aqueous phase was basified with 1M NaOH solution, extracted 3 times with EtOAc and DCM. The combined organic layers were dried over MgSO₄ and concentrated in vacuo to give the desired product as yellow solid.

LC-MS (A): t_R = 0.47 min; $[M+CH_3CN+H]^+$: 246.99.

10 A.2.7 Synthesis of 2-(2-(aminomethyl)-3,5-dichlorophenoxy)ethanol**A.2.7.1 Synthesis of 2-(3,5-dichloro-2-formylphenoxy)ethyl acetate**

To a solution of 4,6-dichlorosalicylaldehyde (3.72 mmol) in 5 mL DMF was added Cs₂CO₃ (3.72 mmol) followed by KI (3.72 mmol) and 2-bromoethyl acetate (8.68 mmol). The reaction mixture was heated to 100°C for 4 h and then stirred at RT for 3 days. The
15 mixture was diluted with EtOAc and washed 3 times with water and then with brine. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept/EtOAc (4/1) to EtOAc gives the desired compound as beige solid.

LC-MS (B): t_R = 0.86 min; $[M+H]^+$: 227.12.

20 A.2.7.2 Synthesis of 2-(3,5-dichloro-2-((hydroxyimino)methyl)phenoxy)ethyl acetate

A solution of 2-(3,5-dichloro-2-formylphenoxy)ethyl acetate (1.48 mmol) in 2.5 mL DMF was cooled to 0°C and NaOAc (1.62 mmol) followed by hydroxylamine HCl (1.62 mmol) were added. The ice bath was removed and the reaction mixture was stirred at RT for 1.5 h. The mixture was diluted with EtOAc and washed once with water and brine. The
25 combined organic layers were dried over MgSO₄ and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept and EtOAc gives the desired compound as white solid.

LC-MS (B): t_R = 0.81 min; $[M+H]^+$: 292.25.

A.2.7.3 Synthesis of 2-(2-(aminomethyl)-3,5-dichlorophenoxy)ethanol

30 A suspension of 2-(3,5-dichloro-2-((hydroxyimino)methyl)phenoxy)ethyl acetate (1.15 mmol) in 2 mL AcOH was cooled to 0°C and zinc dust (4.36 mmol) was added. The reaction mixture was stirred at RT for 1 h. It was filtered over a pad of celite and washed

with EtOAc and MeOH. The filtrate was concentrated and redissolved in water (pH 4 with 2N HCl solution). It was washed once with EtOAc, the aqueous phase was basified with 1M NaOH solution, extracted 3 times with EtOAc and DCM. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired product as white solid.

LC-MS (B): $t_R = 0.46$ min; $[\text{M}+\text{H}]^+$: 236.01.

A.2.8 Synthesis of 2-chloro-3-cyanobenzylamine

A.2.8.1 Synthesis of 3-(bromomethyl)-2-chlorobenzonitrile

A solution of 2-chloro-3-methylbenzonitrile (6.6 mmol) in 25 mL chlorobenzene was heated to 50°C when NBS (7.9 mmol) was added. The flask was purged with Ar before AIBN (0.66 mmol) was added at once still at 50°C . The reaction mixture was stirred at 80°C for 2 h. The solvent was evaporated off, the resulting residue was redissolved in Et_2O and washed 3 times with 1N HCl solution and brine. It was dried over MgSO_4 and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept to Hept/EtOAc (85/15) gives the desired compound as white solid.

LC-MS (A): $t_R = 0.78$ min; ^1H NMR ($(\text{CD}_3)_2\text{SO}$) δ : 7.98 (m, 2H), 7.58 (t, 1H), 4.80 (s, 2H).

A.2.8.2 Synthesis of 2-chloro-3-cyanobenzylamine

To a solution of 3-(bromomethyl)-2-chlorobenzonitrile (0.87 mmol) in 9 mL DMF was added NaN_3 (1.3 mmol) and the resulting brown solution was stirred at RT for 20 min. The reaction mixture was diluted with EtOAc, washed twice with water and brine, dried over MgSO_4 and concentrated in vacuo. The crude azide was redissolved in 4.3 mL THF and 0.1 mL water. Triphenylphosphine (1.04 mmol) was added and the mixture was stirred at RT overnight. The reaction mixture was acidified with 0.1N HCl solution until pH 3 and it was extracted 3 times with Et_2O . The aqueous phase was basified with 1M NaOH solution and extracted 3 times with DCM. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired product as yellowish oil.

LC-MS (A): $t_R = 0.31$ min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 208.04.

A.2.9 Synthesis of 2-chloro-4-cyanobenzylamine

This compound was prepared using a method analogous to that of 2-chloro-3-cyanobenzylamine, 3-chloro-4-methylbenzonitrile replacing 2-chloro-3-methylbenzonitrile.

LC-MS (A): $t_R = 0.31$ min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 208.06.

A.2.10 Synthesis of 2,4-dichloro-6-trifluoromethylbenzylamine

A.2.10.1 Synthesis of 2,4-dichloro-6-trifluoromethylphenylacetic acid methyl ester

To a suspension of CuCl_2 (3.0 mmol) in 30 mL CH_3CN was added tBu-nitrite (4.1 mmol) followed by dropwise addition of 1,1-dichloroethylen (39.1 mmol). A solution of 2,4-dichloro-6-trifluoromethylaniline (2.2 mmol) in 2 mL CH_3CN was slowly added. After stirring at RT overnight, the reaction was quenched with 25% aqueous HCl solution and extracted 3 times with EtOAc. The combined organic layers were dried over MgSO_4 . After removal of the solvent the crude was redissolved in 3 mL MeOH. After addition of 2.4 mL of a 30% solution of NaOMe in MeOH the mixture was refluxed for 5 h. Then, 1.8 mL concentrated H_2SO_4 solution was added at RT and the mixture was heated to reflux for 1 h. After concentrating in vacuo the resulting solid was partitioned between water and DCM. The water phase was extracted 3 times with DCM. The combined organic layers were dried over MgSO_4 . Purification with CC using Hept/EtOAc (10/1) gives the desired product as yellowish oil.

LC-MS (A): t_R = 0.93 min; ^1H NMR ($(\text{CD}_3)_2\text{SO}$) δ : 8.11 (s, 1H), 7.88 (s, 1H), 3.97 (s, 2H), 3.65 (s, 3H).

A.2.10.2 Synthesis of 2,4-dichloro-6-trifluoromethylphenylacetic acid

To a solution of 2,4-dichloro-6-trifluoromethylphenylacetic acid methyl ester (0.93 mmol) in 3 mL THF was added an aq. solution of LiOH (2.8 mmol, 2M). After stirring at RT for 3 days, water was added and the mixture was extracted twice with EtOAc. The aqueous phase was acidified to pH 2-3 with 1N HCl solution and extracted 3 times with EtOAc. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired product as white solid.

LC-MS (A): t_R = 0.78 min; ^1H NMR ($(\text{CD}_3)_2\text{SO}$) δ : 12.8 (brs, 1H), 8.08 (s, 1 H), 7.86 (s, 1 H), 3.86 (s, 2H).

A.2.10.3 Synthesis of 2,4-dichloro-6-trifluoromethylbenzylamine

To a solution of 2,4-dichloro-6-trifluoromethylphenylacetic acid (0.36 mmol) in 3 mL toluene were added Et_3N (0.44 mmol) and DPPA (0.36 mmol). The reaction mixture was heated to 110°C for 3 h, cooled to 0°C and a solution of potassium trimethylsilanolate (0.73 mmol, 1M in THF) was added. After stirring at RT for 30 min, an aqueous solution of 10% citric acid was added and the mixture was extracted twice with Et_2O . The aqueous phase was basified with 1M NaOH solution and extracted 3 times with DCM. The

combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired product as white solid.

LC-MS (A): t_R = 0.48 min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 284.91.

A.2.11 Synthesis of 2,4-dichloro-6-methoxymethylbenzylamine

5 A.2.11.1 Synthesis of 2,4-dichloro-6-(methoxymethyl)benzonitrile

To a suspension of 2-(bromomethyl)-4,6-dichlorobenzonitrile (1.04 mmol) (A.2.5.1) in 2.5 mL MeOH was added a solution of NaOMe (1.27 mmol, 0.5M in MeOH). The reaction mixture was heated to 50°C for 1 h. The mixture was concentrated in vacuo, redissolved in EtOAc and it was then washed twice with an aqueous solution of KHSO_4 , twice with a
10 sat. aq. NaHCO_3 solution and once with brine. The organic layer was dried over MgSO_4 and concentrated in vacuo to give the desired product as orange oil.

LC-MS (A): t_R = 0.84 min; ^1H NMR ($(\text{CD}_3)_2\text{SO}$) δ : 7.97 (s, 1 H), 7.67 (s, 1 H), 4.59 (s, 2H), 3.37 (s, 3H).

A.2.11.2 Synthesis of 2,4-dichloro-6-methoxymethylbenzylamine

15 A solution of BH_3 (3.5 mL, 1M in THF) was added to a solution of 2,4-dichloro-6-(methoxymethyl)benzonitrile (0.88 mmol) in 3 mL THF. The reaction mixture was heated to 60°C for 2 h. At 0°C, 3.5 mL MeOH was dropwise added and the mixture was stirred until gas evolution was finished. An aq. solution of 10% NaOH was added still under cooling. The solvent was removed under vacuo, the residue was diluted with water and
20 extracted 3 times with EtOAc. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired product as orange oil.

LC-MS (A): t_R = 0.45 min; $[\text{M}+\text{H}]^+$: 220.26.

A.2.12 Synthesis of 2-trifluoromethyl-3-chlorobenzylamine

This compound was prepared using a method analogous to that of 2-chloro-3-cyanobenzylamine, 1-chloro-3-methyl-2-(trifluoromethyl)benzene replacing 2-chloro-3-methylbenzonitrile.
25

LC-MS (A): t_R = 0.44 min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 250.99.

A.2.13 Synthesis of 5,7-dichloro-2,3-dihydro-1H-inden-1-amine

A.2.13.1 Synthesis of 5,7-dichloro-2,3-dihydro-1H-inden-1-one O-methyl oxime

30 To a solution of 5,7-dichloro-1-indanone (0.34 mmol) in 2 mL MeOH was added O-methylhydroxylamine HCl (0.34 mmol). The reaction mixture was stirred at RT for 17 h

and then heated to 50°C for 24 h. The mixture was cooled to RT, diluted with water and extracted 3 times with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo to give the desired product as white solid.

LC-MS (A): t_R = 0.99 min; [M+H]⁺: 229.96.

5 **A.2.13.2 Synthesis of 5,7-dichloro-2,3-dihydro-1*H*-inden-1-amine**

A solution of BH₃ (0.6 mL, 1M in THF) was added to a solution of 5,7-dichloro-2,3-dihydro-1*H*-inden-1-one *O*-methyl oxime (0.31 mmol) in 1 mL THF. The reaction mixture was heated to 60°C for 3 days. An aq. 1M NaOH solution was added and heating to 60°C was continued for another 24 h. The solvent was removed under vacuo, the residue was
10 diluted with a sat. aq. NaHCO₃ solution and extracted 3 times with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo to give the desired product as colorless oil.

LC-MS (A): t_R = 0.46 min; [M+H]⁺: 202.03.

A.2.13.3 Chiral separation of 5,7-dichloro-2,3-dihydro-1*H*-inden-1-amine

15 rac 5,7-Dichloro-2,3-dihydro-1*H*-inden-1-amine was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak AY-H, 5 μm, 20x250 mm; Hept/EtOH 90/10 0.1% DEA, flow 16 mL/min), detection: UV 210 nm

Chiral analytic HPLC (Daicel, ChiralPak AY-H, 5 μm, 250x4.6 mm, Hept 0.05% DEA/EtOH 0.05% DEA 90/10, flow 0.8 mL/min), detection: UV 210 nm

20 Enantiomer A: t_R = 7.57 min;

Enantiomer B: t_R = 8.59 min.

A.2.14 Synthesis of 2-bromo-4,6-dichlorobenzylamine

This compound was prepared using a method analogous to that of 2-chloro-3-cyanobenzylamine, 1-bromo-2-(bromomethyl)-3,5-dichlorobenzene [J.Med.Chem., 35
25 (22), 4221 (1992)] replacing 3-(bromomethyl)-2-chlorobenzonitrile.

LC-MS (A): t_R = 0.45 min; [M+CH₃CN+H]⁺: 294.83.

A.2.15 Synthesis of 2-((2-(aminomethyl)-3,5-dichlorobenzyl)oxy)ethanol

A.2.15.1 Synthesis of 2-((3,5-dichloro-2-cyanobenzyl)oxy)ethyl acetate

To a solution of 2-(bromomethyl)-4,6-dichlorobenzonitrile (1.3 mmol) (A.2.5.1) and 2-
30 hydroxyethyl acetate (1.43 mmol) in 7 mL THF was added NaH (1.95 mmol, 60% suspension in oil). The reaction mixture was stirred at RT overnight and then poured into a 1M HCl solution. The mixture was extracted twice with EtOAc. The combined organic

layers were washed with brine, dried over MgSO_4 and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept to Hept/EtOAc (75/25) gives the desired compound as orange oil.

LC-MS (A): t_R = 0.82 min; $[\text{M}+\text{H}]^+$: 287.89.

5 **A.2.15.2 Synthesis of 2-((2-(aminomethyl)-3,5-dichlorobenzyl)oxy)ethanol**

A solution of BH_3 (1.46 mL, 1M in THF) was added to a solution of 2-((3,5-dichloro-2-cyanobenzyl)oxy)ethyl acetate (0.36 mmol) in 1.5 mL MeOH. The reaction mixture was heated to 60°C for 3 h. At 0°C, 1.5 mL MeOH was dropwise added and the mixture was stirred until gas evolution was finished. An aq. solution of 10% NaOH was added still
10 under cooling. The solvent was removed under vacuo, the residue was diluted with water and extracted 3 times with EtOAc. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired product as yellow solid.

LC-MS (A): t_R = 0.43 min; $[\text{M}+\text{H}]^+$: 250.20.

A.2.16 Synthesis of 4,6-dichloro-2,3-dihydro-1H-inden-1-amine

15 This compound was prepared using a method analogous to that of 5,7-dichloro-2,3-dihydro-1H-inden-1-amine (A.2.13), 4,6-dichloro-1-indanone replacing 5,7-dichloro-1-indanone.

LC-MS (A): t_R = 0.50 min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 242.63.

A.2.17 Synthesis of (4,4-difluoro-1-(6-chloropyridin-3-yl)cyclohexyl)methanamine

20 **A.2.17.1 Synthesis of 5-cyano-5-(6-chloropyridin-3-yl)-2-oxocyclohexanecarboxylic acid methyl ester**

To a solution of 2-(6-chloro-3-pyridinyl)-acetonitrile (13.1 mmol) in 35 mL THF were added methylacrylate (26.2 mmol) and KOtBu (15.7 mmol). The reaction mixture was stirred at RT for 1 h. The mixture was acidified with 1N HCl solution and then extracted twice with
25 DCM. The combined organic layers were washed with brine, dried over MgSO_4 and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept/EtOAc (90/10 to 50/50) gives the desired compound as white solid.

LC-MS (A): t_R = 0.74 min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 334.03.

A.2.17.1 Synthesis of 1-(6-chloropyridin-3-yl)-4-oxocyclohexanecarbonitrile

30 A mixture of 5-cyano-5-(6-chloropyridin-3-yl)-2-oxocyclohexanecarboxylic acid methyl ester (10.6 mmol) and LiCl (21.1 mmol) in 15 mL wet DMSO was heated to 120°C under

microwave conditions for 2 h. The reaction mixture was diluted with water and extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried over MgSO_4 and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept/EtOAc (95/5 to 20/80) gives the desired compound as yellow solid.

5 LC-MS (A): t_R = 0.56 min; $[\text{M} + \text{CH}_3\text{CN} + \text{H}]^+$: 276.12.

A.2.17.2 Synthesis of 1-(6-chloropyridin-3-yl)-4,4-difluorocyclohexanecarbonitrile

A solution of 1-(6-chloropyridin-3-yl)-4-oxocyclohexanecarbonitrile (3.89 mmol) in 4 mL DCM was cooled to -78°C , DAST (7.78 mmol) was dropwise added and the mixture was stirred for 24 h allowing to reach slowly RT. The reaction mixture was quenched with sat. aq. NaHCO_3 solution under ice cooling and diluted with DCM. The organic phase was washed with brine, dried over MgSO_4 and concentrated in vacuo. Purification with CC (KP-SILTM from Biotage) using Hept/EtOAc (90/10 to 50/50) gives the desired compound as beige solid.

LC-MS (A): t_R = 0.74 min; $[\text{M} + \text{CH}_3\text{CN} + \text{H}]^+$: 298.00.

15 A.2.17.3 Synthesis of (4,4-difluoro-1-(6-chloropyridin-3-yl)cyclohexyl)methanamine

A solution of 1-(6-chloropyridin-3-yl)-4,4-difluorocyclohexanecarbonitrile (2.02 mmol) in 20 mL THF was added to a solution of BH_3 in THF (6.07 mmol, 1M). After heating to reflux for 1 h, the reaction mixture was cooled in an ice bath before a 2N HCl solution was slowly added. The mixture was then heated to reflux for another 20 min. The reaction mixture was extracted twice with DCM, basified with 1N NaOH solution and extracted 3 times with DCM. The combined organic layers were washed with brine, dried over MgSO_4 and concentrated in vacuo to give the desired product as yellow oil.

LC-MS (A): t_R = 0.46 min; $[\text{M} + \text{CH}_3\text{CN} + \text{H}]^+$: 302.03.

25 A.2.18 Synthesis of 2-(4,4-difluoropiperidin-1-yl)-2-(4-(trifluoromethyl)phenyl)-ethanamine

A.2.18.1 Synthesis of 2-(4,4-difluoropiperidin-1-yl)-2-(4-(trifluoromethyl)phenyl)-acetonitrile

To a solution of 4-(trifluoromethyl)benzaldehyde (5.63 mmol) in 1 mL Et_2O were added TMS-CN (6.19 mmol) followed by ZnI_2 (0.28 mmol). At 0°C , a solution of 4,4-difluoropiperidine HCl (6.19 mmol) and Et_3N (11.8 mmol) in 5 mL MeOH was dropwise added maintaining the temperature below 10°C . The reaction mixture was then heated to reflux for 3 h. After cooling to RT, an aqueous solution of 10% Na_2CO_3 was added and the mixture was extracted 3 times with EtOAc. The combined organic layers were washed

with brine, dried over MgSO_4 and concentrated in vacuo. Purification with CC (KP-NHTM from Biotage) using Hept to Hept/EtOAc (70/30) gives the desired compound as white solid.

LC-MS (A): t_R = 0.92 min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 305.36.

5 **A.2.18.2 Synthesis of 2-(4,4-difluoropiperidin-1-yl)-2-(4-(trifluoromethyl)phenyl)-ethanamine**

To a solution of 2-(4,4-difluoropiperidin-1-yl)-2-(4-(trifluoromethyl)phenyl)-acetonitrile (2.74 mmol) in 20 mL NH_3 in MeOH (7 N) were added at 0°C a solution of thiophene (0.1 mmol, 4% in diisopropylether) followed by Actimet M Raney-Nickel (0.82 mmol). The reaction
10 mixture was allowed to warm to RT. The reaction mixture was stirred under a hydrogen atmosphere for 30 h. The mixture was then filtered over Celite, washed with MeOH and concentrated in vacuo. The residue was redissolved in 5.5 mL Et_2O and 2.8 mL of a 4M HCl solution in dioxane was dropwise added at 0°C. The resulting precipitate was stirred
15 at 0°C for 30 min, filtered off and dried in vacuo to give the desired product as the corresponding HCl salt as white solid.

LC-MS (A): t_R = 0.65 min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 309.02.

A.2.19 Synthesis of 2-(6-methoxypyridin-3-yl)-2-morpholinoethanamine

This compound was prepared using a method analogous to that of 2-(4,4-difluoropiperidin-1-yl)-2-(4-(trifluoromethyl)phenyl)-ethanamine (A.2.18), 6-methoxy-
20 pyridine-3-carboxaldehyde replacing 4-(trifluoromethyl)benzaldehyde and morpholine replacing 4,4-difluoropiperidine HCl.

LC-MS (A): t_R = 0.28 min; $[\text{M}+\text{H}]^+$: 238.09.

A.2.20 Synthesis of 2-(6-methylpyridin-3-yl)-2-morpholinoethanamine

This compound was prepared using a method analogous to that of 2-(4,4-difluoropiperidin-1-yl)-2-(4-(trifluoromethyl)phenyl)-ethanamine (A.2.18), 6-methyl-
25 pyridine-3-carboxaldehyde replacing 4-(trifluoromethyl)benzaldehyde and morpholine replacing 4,4-difluoropiperidine HCl.

LC-MS (A): t_R = 0.12 min; $[\text{M}+\text{H}]^+$: 222.12.

A.2.21 Synthesis of 2-(2-cyclopropylpyrimidin-5-yl)-2-morpholinoethanamine

30 This compound was prepared using a method analogous to that of 2-(4,4-difluoropiperidin-1-yl)-2-(4-(trifluoromethyl)phenyl)-ethanamine (A.2.18), 2-

cyclopropylpyrimidine-5-carbaldehyde replacing 4-(trifluoromethyl)benzaldehyde and morpholine replacing 4,4-difluoropiperidine HCl.

LC-MS (A): t_R = 0.34 min; $[M+H]^+$: 249.10.

A.2.22 Synthesis of 2,4-dichloro-6-D3-methylbenzylamine

5 A.2.22.1 Synthesis of methyl-D3-boronic acid

To a solution of trimethyl borate (17.9 mmol) in 20 mL dry THF was added a solution of methyl-D3-magnesium iodide (10.0 mmol, 1M in Et₂O) over 10 min at -78°C. After stirring at -78°C for 2 h, 5 mL of 1M HCl solution was added. The cooling bath was removed and the mixture was allowed to warm to RT. The reaction was quenched with brine, diluted
10 with Et₂O and the organic phase was washed with brine, dried over MgSO₄ and concentrated in vacuo to a third of its volume.

A.2.22.2 Synthesis of 2,4-dichloro-6-methyl-D3-benzylamine

This compound was prepared using a method analogous to that of 2,4-dichloro-6-cyclopropylbenzylamine (A.2.3), a solution of freshly prepared methyl-D3-boronic acid in
15 Et₂O replacing cyclopropylboronic acid.

LC-MS (D): t_R = 0.86 min; $[M+H]^+$: 193.52.

A.2.23 Synthesis of 5-chloro-2,3-dihydro-1H-inden-1-amine

This compound was prepared using a method analogous to that of 5,7-dichloro-2,3-dihydro-1H-inden-1-amine (A.2.13), 5-chloro-1-indanone replacing 5,7-dichloro-1-
20 indanone.

LC-MS (A): t_R = 0.43 min; $[M+H]^+$: 168.22.

A.2.24 Synthesis of 7-chloro-2,3-dihydro-1H-inden-1-amine

This compound was prepared using a method analogous to that of 5,7-dichloro-2,3-dihydro-1H-inden-1-amine (A.2.13), 7-chloro-1-indanone replacing 5,7-dichloro-1-
25 indanone.

LC-MS (A): t_R = 0.36 min; $[M+H]^+$: 168.22.

A.2.25 Synthesis of 7-bromo-2,3-dihydro-1H-inden-1-amine

This compound was prepared using a method analogous to that of 5,7-dichloro-2,3-dihydro-1H-inden-1-amine (A.2.13), 7-bromo-1-indanone replacing 5,7-dichloro-1-
30 indanone.

LC-MS (C): t_R = 0.48 min; $[M+H]^+$: 211.98.

A.2.26 Synthesis of (2,4,6-trichlorophenyl)methanamine

To a solution of 2,4,6-trichlorobenzonitrile (0.69 mmol) in 2 mL THF was added a solution of BH_3 (2.77 mmol, 1M in THF). The reaction mixture was heated to 40°C for 2 h and then cooled to RT. 1 mL MeOH was added and the mixture was stirred at RT for 30 min. Water was added, the mixture was basified with 1M NaOH solution and extracted twice with EtOAc. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired product as slightly yellow oil.

LC-MS (C): t_R = 0.51 min; $[\text{M}+\text{H}]^+$: 210.13.

A.2.27 Synthesis of (2-(aminomethyl)-3-chlorophenyl)methanol**A.2.27.1 Synthesis of 2-bromo-3-chlorobenzoic acid methyl ester**

To a solution of 2-bromo-3-chlorobenzoic acid (7.29 mmol) in 20 mL DCM and 1 mL DMF was added 1.06 mL thionyl chloride. After stirring at RT overnight, 5 mL MeOH were added and stirring was continued at RT for 1 h. The reaction mixture was cooled in an ice bath, quenched by adding a sat. aq. NaHCO_3 solution and extracted twice with DCM. The combined organic layers were dried over MgSO_4 and concentrated in vacuo to give the desired product as colorless oil.

LC-MS (C): t_R = 0.86 min; $[\text{M}+\text{CH}_3\text{CN}+\text{H}]^+$: 291.94.

A.2.27.2 Synthesis of 3-chloro-2-cyanobenzoic acid methyl ester

To a solution of 2-bromo-3-chlorobenzoic acid methyl ester (3.86 mmol) in 4 mL DMF was added CuCN (4.24 mmol) and the reaction mixture was heated to 90°C overnight. After cooling to 10°C, 10 mL EtOAc and 3 mL 1M NaOH solution were added and stirring was continued at RT for 30 min. The aq. phase was separated and extracted twice with EtOAc. The combined organic layers were washed with brine, dried over MgSO_4 and concentrated in vacuo. Purification by preparative LC-MS (method L) gives the desired product as white solid.

LC-MS (C): t_R = 0.78 min; $[\text{M}+\text{H}]^+$: 196.02.

A.2.27.3 Synthesis of (2-(aminomethyl)-3-chlorophenyl)methanol

To a slurry of ZnCl_2 (0.77 mmol) in 5 mL THF was added LiBH_4 (1.64 mmol, 2M in THF) at RT. After heating to 50°C for 90 min, a solution of 3-chloro-2-cyanobenzoic acid methyl ester (0.81 mmol) in 5 mL THF was slowly added and the mixture was heated to 60°C overnight. The reaction mixture was then cooled to 5°C, acidified with 2M HCl solution and extracted with EtOAc. The aq. phase was basified with 1M NaOH solution, extracted twice with EtOAc, dried over MgSO_4 and concentrated in vacuo to give the desired product as yellowish oil.

LC-MS (C): t_R = 0.38 min; $[M+H]^+$: 172.11.

A.2.28 Synthesis of 2-amino-5,7-dichloro-2,3-dihydro-1*H*-inden-1-one

A.2.28.1 Synthesis of 5,7-dichloro-2-(hydroxyimino)-2,3-dihydro-1*H*-inden-1-one

To a solution of 5,7-dichloro-1-indanone (4.73 mmol) in 20 mL MeOH were carefully
5 added *t*Bu-nitrite (5.20 mmol) and 0.15 mL concentrated HCl solution. The reaction
mixture was heated to 40°C for 24 h, concentrated in vacuo, redissolved in EtOAc and
extracted with sat. aq. NH_4Cl solution. The organic phase was dried over MgSO_4 and
concentrated in vacuo. Purification with CC using Hept/EtOAc (70/30) gives the desired
product as light brown solid.

10 LC-MS (C): t_R = 0.75 min; $[M+H]^+$: 230.00.

A.2.28.2 Synthesis of 2-amino-5,7-dichloro-2,3-dihydro-1*H*-inden-1-one

To a solution of 5,7-dichloro-2-(hydroxyimino)-2,3-dihydro-1*H*-inden-1-one (0.56 mmol) in
4 mL EtOH were added Pd on carbon (5 mg) and 0.1 mL 25% HCl solution. The mixture
was stirred overnight under a hydrogen atmosphere. It was then filtered over a 2 cm pad
15 of celite and washed with EtOH (20 mL) and EtOAc (20 mL). The filtrate was concentrated
in vacuo to give the desired product as brown oil.

LC-MS (C): t_R = 0.50 min; $[M+H]^+$: 216.06.

B. Preparation of examples:

20 B.1 Synthesis of compounds of formula (Ia) (general procedure)

To a solution of the respective acid (II) (0.61 mmol) in 5 mL DCM were added 0.3 mL
DIPEA, HOBT (0.78 mmol) and EDC.HCl (0.78 mmol) followed by the addition of a
solution of the respective amine (III) (0.61 mmol), dissolved in 2 mL DCM. The mixture
was stirred at RT for 6 h and then diluted with DCM and extracted with sat. aq. NaHCO_3
25 solution and water. The organic layer was dried over MgSO_4 , concentrated in vacuo and
the crude was purified by purification methods listed beforehand to give the desired
amides (Ia).

B.2 Synthesis of compounds of formula (Ib) (general procedure)

To a solution of a compound of formula (Ia) (0.61 mmol) in 6 mL THF was added 3-
30 chloroperbenzoic acid (1.84 mmol). The mixture was stirred at RT overnight, diluted with
DCM and extracted twice with sat. aq. NaHCO_3 solution, twice with sat. aq. $\text{Na}_2\text{S}_2\text{O}_3$
solution and brine. The organic layer was dried over MgSO_4 , concentrated in vacuo and

the crude was purified by purification methods listed beforehand to give the desired N-oxides (Ib).

B.3 Separation of stereoisomers of compounds of formula (I)

Additional information for the purification/ separation of mixtures consisting of stereoisomers are summarized in the table below:

Example	Method	TLC conditions	preparative LC-MS
		R _f (eluents)	t _R [min]
1	G	0.49 (9/1 EtOAc/MeOH)	/
2	G	0.38 (9/1 EtOAc/MeOH)	/
6	G	0.25 (EtOAc)	/
7	G	0.13 (EtOAc)	/
13	G	0.35 (DCM/10% MeOH)	/
14	G	0.30 (DCM/10% MeOH)	/
27	U	/	3.85
28	U	/	4.01
29	U	/	2.73
30	U	/	2.87
59	Q	/	2.39
60	Q	/	2.50
70	G	0.50 (EtOAc)	/
71	G	0.43 (EtOAc)	/
74	Q	/	2.44
75	Q	/	2.50
76	G	0.52 (EtOAc)	/
77	G	0.42 (EtOAc)	/

88	G	0.29 (EtOAc)	/
89	G	0.27 (EtOAc)	/
94	G	0.56 (EtOAc)	/
95	G	0.46 (EtOAc)	/
99	G	0.31 (EtOAc)	/
100	G	0.38 (EtOAc)	/
101	G	0.35 (EtOAc)	/
102	G	0.37 (EtOAc)	/
107	G	0.25 (6:4 H/EtOAc)	/
108	G	0.28 (6:4 H/EtOAc)	/
111	G	0.22 (7:3 H/EtOAc)	/
112	G	0.24 (7:3 H/EtOAc)	/

B.4 Chiral separation of compounds of formula (I)

rac-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak

5 IC, 5 μ m, 20x250 mm; Hept/EtOH 50/50, flow 30 mL/min), detection: UV 210 nm

Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, Hept/EtOH 50/50, flow 0.8 mL/min), detection: UV 210 nm

Enantiomer A: t_R = 9.85 min (example 3);

Enantiomer B: t_R = 17.13 min (example 4).

10 rac-3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak IB, 5 μ m, 20x250 mm; Hept/EtOH 90/10, flow 16 mL/min), detection: UV 210 nm

Chiral analytic HPLC (Daicel, ChiralPak IB, 5 μ m, 250x4.6 mm, Hept/EtOH 50/50, flow 0.8 mL/min), detection: UV 210 nm

15

Enantiomer A: t_R = 21.23 min (example 17);

Enantiomer B: t_R = 25.65 min (example 18).

rac-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-hydroxymethyl-benzylamide was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; Hept/EtOH 50/50, flow 16 mL/min), detection: UV 210 nm

- 5 Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, Hept/EtOH 50/50, flow 0.8 mL/min), detection: UV 210 nm

Enantiomer A: t_R = 7.49 min (example 24);

Enantiomer B: t_R = 10.50 min (example 25).

- 10 rac-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-bromo-4,6-dichloro-benzylamide was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; Hept/EtOH 10/90, flow 25 mL/min), detection: UV 210 nm

Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, Hept/EtOH 10/90, flow 1.2 mL/min), detection: UV 210 nm

Enantiomer A: t_R = 5.35 min (example 79);

- 15 Enantiomer B: t_R = 8.52 min (example 80).

Crude 2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide, consisting of 4 stereoisomers was separated into the 2 epimeric mixtures using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; Hept/EtOH 0.1% DEA 20/80, flow 16 mL/min), detection: UV 280 nm.

- 20 Epimeric mixture 1 was separated using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; EtOH/DCM 90/10, flow 16 mL/min), detection: UV 286 nm

Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, EtOH/DCM 90/10, flow 0.8 mL/min), detection: UV 210 nm

Isomer A: t_R = 5.56 min (example 81);

- 25 Isomer B: t_R = 7.79 min (example 82).

Epimeric mixture 2 was separated using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; EtOH/DCM 90/10, flow 20 mL/min), detection: UV 286 nm

Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, EtOH/DCM 90/10, flow 0.8 mL/min), detection: UV 210 nm

- 30 Isomer C: t_R = 6.24 min (example 83);

Isomer D: t_R = 11.20 min (example 84).

Example 76 was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; Hept/EtOH 0.1% DEA 10/90, flow 20 mL/min), detection: UV 210 nm

Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, Hept 0.05% DEA/EtOH 0.05% DEA 10/90, flow 1.0 mL/min), detection: UV 210 nm

Enantiomer A: t_R = 6.67 min (example 85);

Enantiomer B: t_R = 10.42 min (example 86).

- 5 Example 96 was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; Hept/EtOH 50/50, flow 22 mL/min), detection: UV 210 nm

Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, Hept /EtOH 50/50, flow 1.0 mL/min), detection: UV 210 nm

- 10 Enantiomer A: t_R = 7.79 min (example 97);

Enantiomer B: t_R = 13.50 min (example 98).

Crude mixture (enantiomer A of 5,7-dichloro-2,3-dihydro-1*H*-inden-1-amine (A.2.13.3) was used in the synthesis described under B.1) consisting of either 2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*R*)-5,7-dichloro-indan-1-yl)-amide or 2,3-dihydro-furo[2,3-

- 15 *b*]pyridine-3-carboxylic acid ((*S*)-5,7-dichloro-indan-1-yl)-amide was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; Hept/EtOH 10/90 0.1% DEA, flow 20 mL/min), detection: UV 210 nm

Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, Hept 0.05% DEA/EtOH 0.05% DEA 10/90, flow 1.0 mL/min), detection: UV 210 nm

- 20 Enantiomer A: t_R = 5.98 min (example 104);

Enantiomer B: t_R = 10.42 min (example 86).

Crude mixture (enantiomer B of 5,7-dichloro-2,3-dihydro-1*H*-inden-1-amine (A.2.13.3) was used in the synthesis described under B.1) consisting of either 2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*S*)-5,7-dichloro-indan-1-yl)-amide or 2,3-dihydro-furo[2,3-

- 25 *b*]pyridine-3-carboxylic acid ((*R*)-5,7-dichloro-indan-1-yl)-amide was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; Hept/EtOH 10/90 0.1% DEA, flow 20 mL/min), detection: UV 210 nm

Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, Hept 0.05% DEA/EtOH 0.05% DEA 10/90, flow 1.0 mL/min), detection: UV 210 nm

- 30 Enantiomer A: t_R = 6.67 min (example 85);

Enantiomer B: t_R = 8.84 min (example 105).

Example 102 was separated into the respective enantiomers using prep. chiral HPLC (Daicel, ChiralPak IC, 5 μ m, 20x250 mm; Hept/EtOH 20/80, flow 16 mL/min), detection: UV 210 nm

Chiral analytic HPLC (Daicel, ChiralPak IC, 5 μ m, 250x4.6 mm, Hept /EtOH 20/80, flow 0.8.0 mL/min), detection: UV 210 nm

Enantiomer A: t_R = 7.09 min (example 109);

Enantiomer B: t_R = 11.56 min (example 110).

Compound	Name	Purification method	LC-MS		
			LC-MS	t_R [min]	[M+H] +
Example 1	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide (epimer A)	see B.3	E	0.65	291.2
Example 2	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide (epimer B)	see B.3	E	0.66	291.2
Example 3	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide (enantiomer A)	see B.4	E	0.9	337.0
Example 4	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide (enantiomer B)	see B.4	E	0.9	337.0
Example 5	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-benzylamide	G (EtOAc)	E	0.84	323.0
Example 6	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide (epimer A)	see B.3	E	0.73	353.0
Example 7	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide (epimer B)	see B.3	E	0.73	353.0

Example 8	(S)-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide and (R)-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide	P	E	0.61	305.2
Example 9	(S)-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide and (R)-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide	P	E	0.68	367.1
Example 10	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (1-hydroxy-cyclohexylmethyl)-amide	P	E	0.5	291.2
Example 11	rac-3-Fluoro-2,3-dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide	G (4:6 Hept / EtOAc)	E	0.99	355.0
Example 12	rac-4-Fluoro-3,4-dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide	N	E	0.98	369.0
Example 13	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-amide (diastereoisomer A)	see B.3	E	0.72	305.2
Example 14	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-amide (diastereoisomer B)	see B.3	E	0.73	305.2

Example 15	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-fluoro-benzylamide	L	E	0.83	341.0
Example 16	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide	G (EtOAc)	E	0.86	357.1
Example 17	3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide (enantiomer A)	see B.4	E	0.86	351.1
Example 18	3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide (enantiomer B)	see B.4	E	0.86	351.1
Example 19	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [1-(6-chloro-pyridin-3-yl)-cyclohexylmethyl]-amide	M	E	0.81	386.2
Example 20	rac-3-Fluoro-2,3-dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,3-dichloro-benzylamide	M	E	0.9	341.0
Example 21	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-cyclopropyl-benzylamide	M	E	0.98	363.1
Example 22	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-ethyl-benzylamide	L	E	0.97	351.1
Example 23	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-vinyl-benzylamide	L	E	0.94	349.0

Example 24	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-hydroxymethyl-benzylamide (enantiomer A)	see B.4	E	0.73	353.0
Example 25	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-hydroxymethyl-benzylamide (enantiomer B)	see B.4	E	0.73	353.0
Example 26	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methoxy-benzylamide	G (DCM/10% MeOH)	E	0.87	353.0
Example 27	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(2-methyl-pyrimidin-5-yl)-ethyl]-amide (diastereoisomer A)	see B.3	F	0.45	404.2
Example 28	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(2-methyl-pyrimidin-5-yl)-ethyl]-amide (diastereoisomer B)	see B.3	F	0.46	404.2
Example 29	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(2-methyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide (diastereoisomer A)	see B.3	F	0.49	370.2
Example 30	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(2-methyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide (diastereoisomer B)	see B.3	F	0.52	370.1
Example 31	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 3-chloro-2-methyl-benzylamide	H	E	0.76	317.1

Example 32	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2-chloro-4-fluoro-benzylamide	H	E	0.7	321.1
Example 33	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 4-phenoxy-benzylamide	H	E	0.86	361.2
Example 34	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,3-dichloro-benzylamide	H	E	0.77	337.0
Example 35	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 4-chloro-benzylamide	H	E	0.69	303.1
Example 36	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 4-trifluoromethyl-benzylamide	H	E	0.76	337.1
Example 37	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (4-chloro-benzyl)-methyl-amide	H	E	0.76	317.1
Example 38	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	H	E	0.83	351.1
Example 39	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-benzylamide	H	E	0.79	337.1
Example 40	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide	H	E	0.82	371.0
Example 41	rac-8-Oxy-3,4-dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-	M	E	0.73	367.0

	benzylamide				
Example 42	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 3-chloro-2-methyl-benzylamide	H	E	0.81	303.1
Example 43	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-4-fluoro-benzylamide	H	E	0.75	307.1
Example 44	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 4-phenoxy-benzylamide	H	E	0.89	347.1
Example 45	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,3-dichloro-benzylamide	H	E	0.81	323.0
Example 46	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 4-chloro-benzylamide	H	E	0.74	289.1
Example 47	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 4-trifluoromethyl-benzylamide	H	E	0.81	323.1
Example 48	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (4-chloro-benzyl)-methyl-amide	H	E	0.82	303.1
Example 49	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(2,4-dichlorophenyl)-ethyl]-amide	H	E	0.87	337.0
Example 50	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-(2-hydroxy-ethoxy)-benzylamide	G (DCM/10% MeOH)	E	0.79	383.0
Example 51	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-6-hydroxymethyl-	H	E	0.69	367.0

	benzylamide				
Example 52	3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-amide (mixture of 4 stereoisomers)	H	E	0.68	319.2
Example 53	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 3-fluoro-4-trifluoromethoxy-benzylamide	H	E	0.82	371.1
Example 54	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (1-phenyl-cyclohexylmethyl)-amide	H	E	0.92	351.2
Example 55	rac-3-Fluoro-2,3-dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide	G (1:1 Hept / EtOAc)	E	0.94	375.0
Example 56	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-3-cyano-benzylamide	N	E	0.66	314.0
Example 57	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 3-fluoro-4-trifluoromethoxy-benzylamide	H	E	0.86	357.1
Example 58	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [1-(2,4-dichloro-phenyl)-cyclopropyl]-amide	P	E	0.86	363.1
Example 59	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (diastereoisomer A)	see B.3	F	0.87	424.2
Example 60	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-	see B.3	F	0.89	424.2

	2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (diastereoisomer B)				
Example 61	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-4-cyano-benzylamide	N	D	0.68	314.1
Example 62	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(4,4-difluoropiperidin-1-yl)-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (mixture of 4 stereoisomers)	N	F	0.78	458.2
Example 63	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (1-carbamoyl-cyclopentyl)-amide	N	E	0.71	276.2
Example 64	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (2-phenyl-cyclopropyl)-amide (mixture of 4 stereoisomers)	N	E	0.74	281.2
Example 65	(S)-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((1S,2R)-2-hydroxy-indan-1-yl)-amide and (R)-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((1S,2R)-2-hydroxy-indan-1-yl)-amide	N	E	0.58	297.1
Example 66	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (2-carbamoyl-cyclohexyl)-amide (mixture of 4 stereoisomers)	N	E	0.73	290.2
Example 67	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (1-(6-chloropyridin-3-yl)-4,4-difluorocyclohexylmethyl)-amide	L	E	0.74	422.2

Example 68	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-trifluoromethyl-benzylamide	L	E	0.92	391.0
Example 69	(S)-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (R)-indan-1-ylamide and (R)-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (R)-indan-1-ylamide	G (EtOAc)	E	0.73	281.1
Example 70	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [(R)-1-(2,4-dichlorophenyl)-ethyl]-amide (epimer A)	see B.3	E	0.90	337.0
Example 71	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [(R)-1-(2,4-dichlorophenyl)-ethyl]-amide (epimer B)	see B.3	E	0.88	337.0
Example 72	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methoxymethyl-benzylamide	G (1:3 Hept / EtOAc)	E	0.88	367.0
Example 73	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 3-chloro-2-trifluoromethyl-benzylamide	L	E	0.86	357.1
Example 74	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(6-chloropyridin-3-yl)-2-(4,4-difluoropiperidin-1-yl)-ethyl]-amide (diastereoisomer A)	see B.3	F	0.55	423.2
Example 75	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(6-chloropyridin-3-yl)-2-(4,4-difluoropiperidin-1-yl)-ethyl]-amide (diastereoisomer B)	see B.3	F	0.56	423.2

Example 76	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (diastereoisomer A)	see B.3	E	0.89	349.0
Example 77	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (diastereoisomer B)	see B.3	E	0.89	349.1
Example 78	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(4,4-difluoropiperidin-1-yl)-2-(4-trifluoromethylphenyl)-ethyl]-amide (mixture of 4 stereoisomers)	G (EtOAc/5% MeOH)	F	0.69	456.2
Example 79	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-bromo-4,6-dichloro-benzylamide (enantiomer A)	see B.4	E	0.91	400.9
Example 80	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-bromo-4,6-dichloro-benzylamide (enantiomer B)	see B.4	E	0.91	401.0
Example 81	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (isomer A)	see B.4	F	0.56	424.2
Example 82	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (isomer B)	see B.4	F	0.54	424.2
Example 83	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-	see B.4	F	0.54	424.2

	ethyl]-amide (isomer C)				
Example 84	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (isomer D)	see B.4	F	0.56	424.2
Example 85	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (enantiomer A of example 76)	see B.4	E	0.89	349
Example 86	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (enantiomer B of example 76)	see B.4	E	0.89	349
Example 87	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(6-methoxy-pyridin-3-yl)-2-morpholin-4-yl-ethyl]-amide (mixture of 4 stereoisomers)	P	F	0.39	385.2
Example 88	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (3-oxo-indan-1-yl)-amide (diastereoisomer A)	see B.3	E	0.54	295.1
Example 89	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (3-oxo-indan-1-yl)-amide (diastereoisomer B)	see B.3	E	0.56	295.1
Example 90	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(6-methyl-pyridin-3-yl)-2-morpholin-4-yl-ethyl]-amide (mixture of 4 stereoisomers)	T	E	0.34	369.2
Example 91	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(2-cyclopropyl-pyrimidin-5-yl)-2-morpholin-4-yl-	P	F	0.42	396.2

	ethyl]-amide (mixture of 4 stereoisomers)				
Example 92	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-amide (mixture of 4 stereoisomers)	P	F	0.49	423.2
Example 93	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-(2-hydroxy-ethoxymethyl)-benzylamide	G (DCM/10% MeOH)	E	0.76	397.1
Example 94	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (4,6-dichloro-indan-1-yl)-amide (diastereoisomer A)	see B.3	E	0.95	349
Example 95	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (4,6-dichloro-indan-1-yl)-amide (diastereoisomer B)	see B.3	E	0.95	349
Example 96	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-trideuteromethyl-benzylamide	G (EtOAc)	E	0.96	340.2
Example 97	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-trideuteromethyl-benzylamide (enantiomer A)	see B.4	E	0.96	340.2
Example 98	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-trideuteromethyl-benzylamide (enantiomer B)	see B.4	E	0.96	340.2
Example 99	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5-chloro-indan-1-	see B.3	E	0.91	315.2

	yl)-amide (diastereoisomer A)				
Example 100	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5-chloro-indan-1-yl)-amide (diastereoisomer B)	see B.3	E	0.91	315.2
Example 101	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide (diastereoisomer A)	see B.3	E	0.83	315.2
Example 102	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide (diastereoisomer B)	see B.3	E	0.83	315.2
Example 103	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-4-trifluoromethyl-benzylamide	N	E	0.95	357.2
Example 104	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (enantiomer A of example 77)	see B.4	E	0.96	349.2
Example 105	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (enantiomer B of example 77)	see B.4	E	0.96	349.1
Example 106	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [3-(2,4-dichlorophenyl)-propyl]-amide	G (1:1 Hept / EtOAc)	E	1.02	351.2
Example 107	2,3-dihydrofuro[2,3- <i>b</i>]pyridine-3-carboxylic acid ((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-amide (epimer A)	see B.3	E	0.86	295.2
Example 108	2,3-dihydrofuro[2,3- <i>b</i>]pyridine-3-carboxylic acid ((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-amide	see B.3	E	0.85	295.2

	(epimer B)				
Example 109	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide (enantiomer A of example 102)	see B.4	E	0.83	315.2
Example 110	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide (enantiomer B of example 102)	see B.4	E	0.83	315.2
Example 111	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((R)-8-chloro-1,2,3,4-tetrahydro-naphthalen-1-yl)-amide (epimer A)	see B.3	E	0.89	329.2
Example 112	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((R)-8-chloro-1,2,3,4-tetrahydro-naphthalen-1-yl)-amide (epimer B)	see B.3	E	0.88	329.2
Example 113	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-bromo-indan-1-yl)-amide (mixture of 4 stereoisomers)	L	E	0.85	359.1
Example 114	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4,6-trichloro-benzylamide	L	E	0.95	357.1
Example 115	rac-7-Oxy-2,3-dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide	precipitation from EtOAc	E	0.78	353.2
Example 116	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-1-oxo-indan-2-yl)-amide (mixture of 4 stereoisomers)	M	E	0.85	363.1

Example 117	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 4-chloro-2-hydroxymethyl-benzylamide	N	E	0.68	319.2
Example 118	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-6-hydroxymethyl-benzylamide	N	E	0.66	319.2

II. Biological assays

In vitro assay

The P2X₇ receptor antagonistic activity of the compounds of formula (I) is determined in accordance with the following experimental method.

Experimental method:

Cell line generation and YO-PRO assay

Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole blood using the Qiagen RNeasy kit (Qiagen, CH) according to the manufacturer's instructions. Subsequently cDNA was made (Superscript II, Invitrogen AG, CH) and the human P2X7 gene (genbank ref. BC011913) was amplified with the following primers: ATCGCGGCCGCTCAGTAAGGACTCTTGAAGCCACT and CGCCGCTAGCACCATGCGGCCTGCTGCAGCTGCA. The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL – 1573, Manassas, VA, USA) were transfected with the pcDNA3.1 (+).hP2X7 plasmid using lipofectamine 2000 (Invitrogen AG, CH) according to the manufacturer's instructions. Following a 24h exposure to DNA, cells were trypsinized and re-seeded at low density in the presence of 250 µg Geneticin. Geneticin resistant cells were then selected during two consecutive rounds of cloning by serial limiting dilution with visual inspection. Individual clones were screened for P2X7 expression by applying ATP and recording the resultant uptake of YO-PRO1. Specific cell clones were chosen based on RNA and protein expression. HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37°C in a humidified 5% CO₂ incubator (split 1/5 every 3 – 4 days with DMEM, 10 % FCS, 1% Penicillin/Streptomycin, 250 µg/ml Geneticin).

Adherent cells were detached by incubation with Trypsine (1 ml per 165 cm² dish) for 2 minutes, then washed off with 10 ml PBS (without Mg²⁺ and Ca²⁺), and resuspended in DMEM, 10 % FCS, 1 % Penicillin/Streptomycin, no Geneticin. 10'000 cells per well (48 hours before the assay) or 25'000 cells per well (Vi-cell XR (Beckman Coulter) (24 hours before the assay) in 50 µl full medium were seeded on 384-well black-wall, clear bottom plates, that were coated before with 10 µl per well Poly-L-Lysine, incubated for 30 – 60 minutes at 37° C and washed once with PBS. Medium was removed from cells and 50 µl of assay buffer containing 0.5 µM YO-PRO-1 was added into the wells. Solutions of antagonist compounds were prepared by serial dilutions of a 10 mM DMSO solution of the antagonist into PBS using a BioMek (Beckman Coulter). Each concentration was performed in duplicate. For IC₅₀ measurements 10 concentration points were measured (10 µM being the highest concentration followed by 9 serial dilution steps 1/3). The cells were incubated with the antagonists of the present invention together with ATP at a final concentration of 250 µM for 90 minutes. During this time period, four time points were taken. Each time point comprised the average of several measurements made within a few seconds. Fluorescence was measured in the FLIPR tetra (Molecular Devices) using the filters appropriate for YO-PRO-1 fluorescence (excitation 485/20, emission 530/25). The FLIPR tetra was equipped with Molecular Devices Screen Works system control software to define and run experimental protocols. For antagonist activity measurements, the maximal intensity was expressed as a percentage of that induced by the EC₅₀ value for agonist activation (0.25 mM ATP for HEK-293 cells expressing human recombinant P2X₇ receptor). For IC₅₀ measurements the maximum intensity is plotted against the concentration of compound to determine IC₅₀ values.

Antagonistic activities with respect to the P2X₇ receptor (IC₅₀ values) of exemplified compounds are displayed in *Table 1*.

Table 1

Compound	Name	IC ₅₀ [nM]
Example 1	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide (epimer A)	1070
Example 2	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide (epimer B)	106
Example 3	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide (enantiomer A)	18.3

Example 4	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide (enantiomer B)	2.9
Example 5	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-benzylamide	59.2
Example 6	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide (epimer A)	621
Example 7	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide (epimer B)	117
Example 8	(S)-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide and (R)-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide	127
Example 9	(S)-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide and (R)-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide	70.8
Example 10	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (1-hydroxy-cyclohexylmethyl)-amide	3175
Example 11	rac-3-Fluoro-2,3-dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide	4.8
Example 12	rac-4-Fluoro-3,4-dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide	3.1
Example 13	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-amide (diastereoisomer A)	813
Example 14	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-amide (diastereoisomer B)	117
Example 15	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-fluoro-benzylamide	66.8
Example 16	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide	12.6

Example 17	3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide (enantiomer A)	1.3
Example 18	3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide (enantiomer B)	1.6
Example 19	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [1-(6-chloro-pyridin-3-yl)-cyclohexylmethyl]-amide	6.3
Example 20	rac-3-Fluoro-2,3-dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,3-dichloro-benzylamide	67.9
Example 21	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-cyclopropyl-benzylamide	12.9
Example 22	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-ethyl-benzylamide	1.5
Example 23	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-vinyl-benzylamide	12.2
Example 24	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-hydroxymethyl-benzylamide (enantiomer A)	39.4
Example 25	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-hydroxymethyl-benzylamide (enantiomer B)	2.7
Example 26	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methoxy-benzylamide	25.6
Example 27	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(2-methyl-pyrimidin-5-yl)-ethyl]-amide (diastereoisomer A)	1363
Example 28	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(2-methyl-pyrimidin-5-yl)-ethyl]-amide (diastereoisomer B)	58.9
Example 29	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(2-methyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide (diastereoisomer A)	1685
Example 30	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(2-	225

	methyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide (diastereoisomer B)	
Example 31	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 3-chloro-2-methyl-benzylamide	16.0
Example 32	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2-chloro-4-fluoro-benzylamide	25.0
Example 33	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 4-phenoxy-benzylamide	255
Example 34	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,3-dichloro-benzylamide	10.7
Example 35	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 4-chloro-benzylamide	475
Example 36	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 4-trifluoromethyl-benzylamide	334
Example 37	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (4-chloro-benzyl)-methyl-amide	758
Example 38	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	67.1
Example 39	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-benzylamide	11.8
Example 40	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide	2.7
Example 41	rac-8-Oxy-3,4-dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4- carboxylic acid 2,4-dichloro-6-methyl-benzylamide	16.3
Example 42	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 3- chloro-2-methyl-benzylamide	46.9
Example 43	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2- chloro-4-fluoro-benzylamide	86.8
Example 44	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 4- phenoxy-benzylamide	1117

Example 45	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,3-dichloro-benzylamide	37.2
Example 46	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 4-chloro-benzylamide	795
Example 47	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 4-trifluoromethyl-benzylamide	1248
Example 48	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (4-chloro-benzyl)-methyl-amide	1087
Example 49	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	157
Example 50	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-(2-hydroxy-ethoxy)-benzylamide	54.6
Example 51	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 2,4-dichloro-6-hydroxymethyl-benzylamide	5.6
Example 52	3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-amide (mixture of 4 stereoisomers)	276
Example 53	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid 3-fluoro-4-trifluoromethoxy-benzylamide	1185
Example 54	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (1-phenyl-cyclohexylmethyl)-amide	25.8
Example 55	rac-3-Fluoro-2,3-dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide	41.6
Example 56	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-3-cyano-benzylamide	125
Example 57	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 3-fluoro-4-trifluoromethoxy-benzylamide	3065
Example 58	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid [1-(2,4-dichloro-phenyl)-cyclopropyl]-amide	2700
Example 59	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-	346

	morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (diastereoisomer A)	
Example 60	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (diastereoisomer B)	29.0
Example 61	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-4-cyano-benzylamide	389
Example 62	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (mixture of 4 stereoisomers)	46.9
Example 63	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (1-carbamoyl-cyclopentyl)-amide	3850
Example 64	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (2-phenyl-cyclopropyl)-amide (mixture of 4 stereoisomers)	4850
Example 65	(S)-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((1S,2R)-2-hydroxy-indan-1-yl)-amide and (R)-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((1S,2R)-2-hydroxy-indan-1-yl)-amide	3400
Example 66	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (2-carbamoyl-cyclohexyl)-amide (mixture of 4 stereoisomers)	5880
Example 67	rac-3,4-Dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i>]pyridine-4-carboxylic acid (1-(6-chloropyridin-3-yl)-4,4-difluorocyclohexylmethyl)-amide	7.3
Example 68	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-trifluoromethyl-benzylamide	13.8
Example 69	(S)-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (R)-indan-1-ylamide and (R)-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (R)-indan-1-ylamide	400
Example 70	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [(R)-1-(2,4-dichloro-phenyl)-ethyl]-amide (epimer A)	110
Example 71	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [(R)-1-(2,4-dichloro-phenyl)-ethyl]-amide (epimer B)	36.5

Example 72	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methoxymethyl-benzylamide	14.6
Example 73	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 3-chloro-2-trifluoromethyl-benzylamide	20.2
Example 74	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(6-chloro-pyridin-3-yl)-2-(4,4-difluoro-piperidin-1-yl)-ethyl]-amide (diastereoisomer A)	120
Example 75	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(6-chloro-pyridin-3-yl)-2-(4,4-difluoro-piperidin-1-yl)-ethyl]-amide (diastereoisomer B)	35.3
Example 76	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (diastereoisomer A)	20.6
Example 77	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (diastereoisomer B)	4.7
Example 78	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(4-trifluoromethyl-phenyl)-ethyl]-amide (mixture of 4 stereoisomers)	122
Example 79	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-bromo-4,6-dichloro-benzylamide (enantiomer A)	51.1
Example 80	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-bromo-4,6-dichloro-benzylamide (enantiomer B)	4.1
Example 81	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (isomer A)	7523
Example 82	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (isomer B)	2230
Example 83	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (isomer C)	124


Example 84	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide (isomer D)	20.8
Example 85	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (enantiomer A of example 76)	9.5
Example 86	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (enantiomer B of example 76)	164
Example 87	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(6-methoxy-pyridin-3-yl)-2-morpholin-4-yl-ethyl]-amide (mixture of 4 stereoisomers)	978
Example 88	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (3-oxo-indan-1-yl)-amide (diastereoisomer A)	1450
Example 89	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (3-oxo-indan-1-yl)-amide (diastereoisomer B)	2508
Example 90	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(6-methyl-pyridin-3-yl)-2-morpholin-4-yl-ethyl]-amide (mixture of 4 stereoisomers)	1149
Example 91	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-(2-cyclopropyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide (mixture of 4 stereoisomers)	215
Example 92	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-amide (mixture of 4 stereoisomers)	82.2
Example 93	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-(2-hydroxy-ethoxymethyl)-benzylamide	11.4
Example 94	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (4,6-dichloro-indan-1-yl)-amide (diastereoisomer A)	570
Example 95	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (4,6-dichloro-indan-1-yl)-amide (diastereoisomer B)	978
Example 96	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-	2.7

	dichloro-6-trideuteromethyl-benzylamide	
Example 97	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-trideuteromethyl-benzylamide (enantiomer A)	20
Example 98	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-trideuteromethyl-benzylamide (enantiomer B)	1.8
Example 99	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5-chloro-indan-1-yl)-amide (diastereoisomer A)	301
Example 100	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5-chloro-indan-1-yl)-amide (diastereoisomer B)	59.9
Example 101	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide (diastereoisomer A)	212
Example 102	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide (diastereoisomer B)	11.0
Example 103	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-4-trifluoromethyl-benzylamide	80.4
Example 104	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (enantiomer A of example 77)	5100
Example 105	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide (enantiomer B of example 77)	1.3
Example 106	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid [3-(2,4-dichloro-phenyl)-propyl]-amide	346
Example 107	2,3-dihydrofuro[2,3- <i>b</i>]pyridine-3-carboxylic acid ((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-amide (epimer A)	1222
Example 108	2,3-dihydrofuro[2,3- <i>b</i>]pyridine-3-carboxylic acid ((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-amide (epimer B)	191
Example 109	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide (enantiomer A of example 102)	10000
Example 110	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide (enantiomer B of example 102)	5.5
Example 111	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((R)-8-	221

	chloro-1,2,3,4-tetrahydro-naphthalen-1-yl)-amide (epimer A)	
Example 112	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid ((R)-8-chloro-1,2,3,4-tetrahydro-naphthalen-1-yl)-amide (epimer B)	9.5
Example 113	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (7-bromo-indan-1-yl)-amide (mixture of 4 stereoisomers)	35.9
Example 114	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4,6-trichloro-benzylamide	12.5
Example 115	rac-7-Oxy-2,3-dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide	35.4
Example 116	2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid (5,7-dichloro-1-oxo-indan-2-yl)-amide (mixture of 4 stereoisomers)	9010
Example 117	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 4-chloro-2-hydroxymethyl-benzylamide	1487
Example 118	rac-2,3-Dihydro-furo[2,3- <i>b</i>]pyridine-3-carboxylic acid 2-chloro-6-hydroxymethyl-benzylamide	304

Claims

1. A compound of the formula (I),



5 wherein

n represents 1 or 2;

X represents -N- or -N(O)-;

R¹ represents hydrogen or halogen;

R² represents hydrogen or methyl; and

10 **R**³ represents

- aryl-(C₁-C₃)alkyl, which is in the alkyl part optionally mono-substituted with hydroxy or heterocyclyl; and which is in the aryl part mono-, di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, hydroxy-(C₁-C₃)alkyl, hydroxy-(C₂-C₃)alkoxy, hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl, (C₁-C₂)alkoxy-(C₁-C₂)alkyl, (C₁-C₃)fluoroalkyl, (C₁-C₃)fluoroalkoxy, cyano, halogen and phenoxy; or
- heteroaryl-(C₁-C₃)alkyl, which is in the alkyl part mono-substituted with heterocyclyl; and which is in the heteroaryl part mono-, di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, (C₁-C₃)fluoroalkyl and halogen; or
- (C₃-C₇)cycloalkyl, which is monosubstituted with -C(O)NH₂ or an optionally mono-, di- or tri-substituted phenyl, wherein the substituents are selected from halogen; or
- (C₅-C₇)cycloalkyl, which is optionally mono-substituted with hydroxy or oxo; and which is annelated with an optionally mono-, di- or tri-substituted phenyl, wherein the substituents are selected from halogen; or
- (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl, which is in the alkyl part optionally mono-substituted with hydroxy; and which is in the cycloalkyl part optionally di-substituted with halogen and optionally mono-substituted with hydroxy, aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono-, di- or tri-substituted with halogen;

or a salt of such a compound.

2. A compound of formula (I) according to claim 1, wherein

n represents 1 or 2;

X represents -N- or -N(O)-;

R¹ represents hydrogen or fluorine;

5 **R**² represents hydrogen; and

R³ represents

- aryl-methyl, which is in the aryl part di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, hydroxy-(C₁-C₃)alkyl, hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl, (C₁-C₂)alkoxy-(C₁-C₂)alkyl, (C₁-C₃)fluoroalkyl and halogen; or
- cyclopentyl, which is annelated with an mono- or di-substituted phenyl, wherein the substituents are selected from halogen; or
- cyclohexyl-methyl, which is in the cyclohexyl part optionally di-substituted with fluorine and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono- or di- substituted with halogen;

or a salt of such a compound.

3. A compound of formula (I) according to any one of claims 1 or 2, wherein

n represents 1;

20 or a salt of such a compound.

4. A compound of formula (I) according to any one of claims 1 or 2, wherein

n represents 2;

or a salt of such a compound.

5. A compound of formula (I) according to any one of claims 1 to 4, wherein

25 **X** represents -N-;

or a salt of such a compound.

6. A compound of formula (I) according to any one of claims 1 to 5, wherein

R² represents hydrogen;

or a salt of such a compound.

30 7. A compound of formula (I) according to any one of claims 1 or 3 to 6, wherein

R³ represents

- aryl-(C₁-C₂)alkyl, which is in the aryl part mono-, di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, hydroxy-(C₁-C₃)alkyl, hydroxy-

(C₂-C₃)alkoxy-(C₁-C₂)alkyl, (C₁-C₂)alkoxy-(C₁-C₂)alkyl, (C₁-C₃)fluoroalkyl and halogen; or

- (C₅-C₇)cycloalkyl, which is annelated with an optionally mono-, di- or tri-substituted phenyl, wherein the substituents are selected from halogen; or

- 5 • (C₅-C₇)cycloalkyl-(C₁-C₂)alkyl, which is in the cycloalkyl part optionally di-substituted with halogen and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl groups are optionally mono- or di- substituted with halogen;

or a salt of such a compound.

8. A compound of formula (I) according to any one of claims 1 to 6, wherein

10 **R³** represents

- aryl-methyl, which is in the aryl part di- or tri-substituted, wherein the substituents are independently selected from the group consisting of (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, (C₁-C₄)alkoxy, hydroxy-(C₁-C₃)alkyl, hydroxy-(C₂-C₃)alkoxy-(C₁-C₂)alkyl, (C₁-C₂)alkoxy-(C₁-C₂)alkyl, (C₁-C₃)fluoroalkyl and

15 halogen; or

- cyclopentyl, which is annelated with an mono- or di-substituted phenyl, wherein the substituents are selected from halogen; or

- cyclohexyl-methyl, which is in the cyclohexyl part optionally di-substituted with fluorine and mono-substituted with aryl or heteroaryl, wherein the aryl or heteroaryl

20 groups are optionally mono- or di- substituted with halogen;

or a salt of such a compound.

9. A compound of formula (I) according to claim 1, selected from the group consisting of:

(S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide;

25 (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide;

(S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;

(R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;

2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-benzylamide;

30 (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide;

(R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide;

- 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid ((*S*)-1-cyclohexyl-2-hydroxy-ethyl)-amide;
- 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid [(*S*)-1-(2,4-dichloro-phenyl)-2-hydroxy-ethyl]-amide;
- 5 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (1-hydroxy-cyclohexylmethyl)-amide;
- 3-Fluoro-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;
- 4-Fluoro-3,4-dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-
- 10 benzylamide;
- (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*S*^{*})-1-cycloheptyl-2-hydroxy-ethyl)-amide;
- (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((*R*^{*})-1-cycloheptyl-2-hydroxy-ethyl)-amide;
- 15 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-fluoro-benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide;
- (*S*)-3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;
- (*R*)-3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-
- 20 benzylamide;
- 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid [1-(6-chloro-pyridin-3-yl)-cyclohexylmethyl]-amide;
- 3-Fluoro-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,3-dichloro-benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-cyclopropyl-benzylamide;
- 25 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-ethyl-benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-vinyl-benzylamide;
- (*S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-hydroxymethyl-benzylamide;
- (*R*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-hydroxymethyl-
- 30 benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methoxy-benzylamide;
- (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*S*^{*})-2-(4,4-difluoro-piperidin-1-yl)-2-(2-methyl-pyrimidin-5-yl)-ethyl]-amide;
- (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*R*^{*})-2-(4,4-difluoro-piperidin-1-yl)-2-
- 35 (2-methyl-pyrimidin-5-yl)-ethyl]-amide;

- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S*)-2-(2-methyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide;
(S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(R*)-2-(2-methyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide;
- 5 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 3-chloro-2-methyl-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2-chloro-4-fluoro-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 4-phenoxy-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,3-dichloro-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 4-chloro-benzylamide;
- 10 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 4-trifluoromethyl-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (4-chloro-benzyl)-methyl-amide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-benzylamide;
- 15 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide;
8-Oxy-3,4-dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-methyl-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 3-chloro-2-methyl-benzylamide;
- 20 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-4-fluoro-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 4-phenoxy-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,3-dichloro-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 4-chloro-benzylamide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 4-trifluoromethyl-benzylamide;
- 25 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (4-chloro-benzyl)-methyl-amide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide;
2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-(2-hydroxy-ethoxy)-benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 2,4-dichloro-6-hydroxymethyl-
- 30 benzylamide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-amide;
3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid 3-fluoro-4-trifluoromethoxy-benzylamide;

- 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (1-phenyl-cyclohexylmethyl)-amide;
- 3-Fluoro-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-3-trifluoromethyl-benzylamide;
- 5 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-3-cyano-benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 3-fluoro-4-trifluoromethoxy-benzylamide;
- 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid [1-(2,4-dichloro-phenyl)-cyclopropyl]-amide;
- (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*S*^{*})-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- 10 (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*R*^{*})-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-4-cyano-benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- 15 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (1-carbamoyl-cyclopentyl)-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (2-phenyl-cyclopropyl)-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((1*S*,2*R*)-2-hydroxy-indan-1-yl)-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (2-carbamoyl-cyclohexyl)-amide;
- 20 3,4-Dihydro-2*H*-pyrano[2,3-*b*]pyridine-4-carboxylic acid (1-(6-chloropyridin-3-yl)-4,4-difluorocyclohexylmethyl)-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-trifluoromethyl-benzylamide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (*R*)-indan-1-ylamide;
- 25 (*S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*R*)-1-(2,4-dichloro-phenyl)-ethyl]-amide;
- (*R*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*R*)-1-(2,4-dichloro-phenyl)-ethyl]-amide;
- 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methoxymethyl-benzylamide;
- 30 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 3-chloro-2-trifluoromethyl-benzylamide;
- (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*S*^{*})-2-(6-chloro-pyridin-3-yl)-2-(4,4-difluoro-piperidin-1-yl)-ethyl]-amide;
- (*S*^{*})-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(*R*^{*})-2-(6-chloro-pyridin-3-yl)-2-(4,4-difluoro-piperidin-1-yl)-ethyl]-amide;
- 35

- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S*)-5,7-dichloro-indan-1-yl)-amide;
 (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R*)-5,7-dichloro-indan-1-yl)-amide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-2-(4-trifluoromethyl-phenyl)-ethyl]-amide;
- 5 (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-bromo-4,6-dichloro-benzylamide;
 (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-bromo-4,6-dichloro-benzylamide;
 (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S)-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
 (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(R)-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- 10 (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(S)-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
 (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [(R)-2-morpholin-4-yl-2-(2-trifluoromethyl-pyrimidin-5-yl)-ethyl]-amide;
- 15 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(6-methoxy-pyridin-3-yl)-2-morpholin-4-yl-ethyl]-amide;
 (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S*)-3-oxo-indan-1-yl)-amide;
 (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R*)-3-oxo-indan-1-yl)-amide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(6-methyl-pyridin-3-yl)-2-morpholin-4-yl-ethyl]-amide;
- 20 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-(2-cyclopropyl-pyrimidin-5-yl)-2-morpholin-4-yl-ethyl]-amide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [2-morpholin-4-yl-2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-amide;
- 25 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-(2-hydroxy-ethoxymethyl)-benzylamide;
 (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S*)-4,6-dichloro-indan-1-yl)-amide;
 and
 (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R*)-4,6-dichloro-indan-1-yl)-amide;
- 30 or a salt of such a compound.

10. A compound of formula (I) according to claim 1, selected from the group consisting of:

- (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-trideuteromethyl-benzylamide;
 (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-trideuteromethyl-benzylamide;
- 35

- (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S*)-5-chloro-indan-1-yl)-amide;
 (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R*)-5-chloro-indan-1-yl)-amide;
 (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((S*)-7-chloro-indan-1-yl)-amide;
 (S*)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R*)-7-chloro-indan-1-yl)-amide;
 5 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-4-trifluoromethyl-benzylamide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (5,7-dichloro-indan-1-yl)-amide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid [3-(2,4-dichloro-phenyl)-propyl]-amide;
 (S)-2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid ((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-amide;
 10 (R)-2,3-dihydrofuro[2,3-*b*]pyridine-3-carboxylic acid ((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-amide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (7-chloro-indan-1-yl)-amide;
 (S)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R)-8-chloro-1,2,3,4-tetrahydro-naphthalen-1-yl)-amide;
 15 (R)-2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid ((R)-8-chloro-1,2,3,4-tetrahydro-naphthalen-1-yl)-amide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (7-bromo-indan-1-yl)-amide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4,6-trichloro-benzylamide;
 7-Oxy-2,3-dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2,4-dichloro-6-methyl-
 20 benzylamide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid (5,7-dichloro-1-oxo-indan-2-yl)-amide;
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 4-chloro-2-hydroxymethyl-benzylamide;
 and
 2,3-Dihydro-furo[2,3-*b*]pyridine-3-carboxylic acid 2-chloro-6-hydroxymethyl-benzylamide;
 25 or a salt of such a compound.

11. A compound of formula (I) according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use as a medicament.

12. A pharmaceutical composition containing, as active principle, a compound of formula (I) according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof,
 30 and at least one therapeutically inert excipient.

13. Use of a compound of formula (I) according to any one of claims 1 to 10, or of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of a disease selected from pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways;

cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.

- 5 **14.** A compound of formula (I) according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a disease selected from pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an
10 inflammatory or immunological component.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2013/050479

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D491/048 A61K31/4355 A61P29/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2005/111003 A1 (ABBOTT LABORATORIES) 24 November 2005 (2005-11-24) cited in the application page 1, line 12 - page 3, line 21; claims; example 63C	1-14
A	WO 2009/023623 A1 (NEUROGEN CORPORATION) 19 February 2009 (2009-02-19) claims; examples ----- -/--	1-14



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 April 2013

Date of mailing of the international search report

14/05/2013

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Helps, Ian

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2013/050479

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	C. B. MADSEN-DUGGAN ET. AL.: "Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: Synthesis, SAR and biological evaluation.", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 12, 21 April 2010 (2010-04-21), pages 3750-3754, XP002695622, table 5	1-14
E	----- WO 2013/014587 A1 (ACTELION PHARMACEUTICALS LTD.) 31 January 2013 (2013-01-31) page 1 - page 2; claims; examples -----	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2013/050479

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005111003 A1	24-11-2005	CA 2565211 A1 EP 1747206 A1 JP 2007535553 A US 2006052374 A1 US 2007049584 A1 US 2008171733 A1 US 2012329772 A1 WO 2005111003 A1	24-11-2005 31-01-2007 06-12-2007 09-03-2006 01-03-2007 17-07-2008 27-12-2012 24-11-2005
WO 2009023623 A1	19-02-2009	AU 2008286946 A1 CA 2691512 A1 CN 101778850 A CO 6251319 A2 EA 200971085 A1 EP 2185560 A1 JP 2010535816 A KR 20100066422 A NZ 582056 A SG 183699 A1 WO 2009023623 A1	19-02-2009 19-02-2009 14-07-2010 21-02-2011 30-06-2010 19-05-2010 25-11-2010 17-06-2010 31-08-2012 27-09-2012 19-02-2009
WO 2013014587 A1	31-01-2013	NONE	